0001477932-17-003905.txt : 20170814 0001477932-17-003905.hdr.sgml : 20170814 20170814113412 ACCESSION NUMBER: 0001477932-17-003905 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170814 DATE AS OF CHANGE: 20170814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RenovaCare, Inc. CENTRAL INDEX KEY: 0001016708 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980170247 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30156 FILM NUMBER: 171028324 BUSINESS ADDRESS: STREET 1: 430 PARK AVE. STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 888-398-0202 MAIL ADDRESS: STREET 1: 430 PARK AVE. STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: Janus Resources, Inc. DATE OF NAME CHANGE: 20110110 FORMER COMPANY: FORMER CONFORMED NAME: ENTHEOS TECHNOLOGIES INC DATE OF NAME CHANGE: 20001002 FORMER COMPANY: FORMER CONFORMED NAME: WHATSONLINE COM INC DATE OF NAME CHANGE: 19990722 10-Q 1 rcar_10q.htm FORM 10-Q rcar_10q.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2017

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ___________

 

Commission file number 000-30156

 

RENOVACARE, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

98-0384030

(State or other jurisdiction of incorporation)

(I.R.S. Employer Identification No.)

 

430 Park Avenue

Suite 702

New York, NY 10022

(Address of principal executive offices)

 

888-398-0202

(Registrant's telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

¨

Accelerated filer

¨

Non-accelerated filer

¨

(Do not check if a smaller reporting company)

Smaller reporting company

¨

Emerging Growth Company

x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act): Yes ¨ No x

 

As of August 8, 2017, the registrant had 75,225,418 shares of its common stock, par value $0.00001 per share, issued and outstanding.

 

 
 
 

 

RENOVACARE, INC.

  FORM 10-Q

For The Quarter Ended June 30, 2017

 

TABLE OF CONTENTS

 

Page #

PART I - FINANCIAL INFORMATION

Item 1.

Financial Statements

3

Consolidated Balance Sheets

3

Consolidated Statements of Operations

4

Consolidated Statements of Stockholders’ Equity

5

Consolidated Statements of Cash Flows

6

Notes to Consolidated Financial Statements

7

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

24

Item 4.

Controls and Procedures

24

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

25

Item 1A.

Risk Factors

25

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

25

Item 6.

Exhibits

26

Signatures

27

 

 
2
 
Table of Contents

 

PART I

Item 1. Financial Statements

 

RENOVACARE, INC

CONSOLIDATED BALANCE SHEETS

AS OF JUNE 30, 2017 AND DECEMBER 31, 2016

 

 

 

June 30,

 

 

December 31,

 

 

 

2017

 

 

2016

 

 

 

(Unaudited)

 

 

 

 

ASSETS

Current assets

 

 

 

 

 

 

Cash and cash equivalents

 

$ 442,941

 

 

$ 418,031

 

Prepaid expenses

 

 

23,046

 

 

 

31,535

 

Total current assets

 

 

465,987

 

 

 

449,566

 

 

 

 

 

 

 

 

 

 

Equipment, net of accumulated depreciation of $211 and $53, respectively

 

 

740

 

 

 

898

 

Intangible assets

 

 

152,854

 

 

 

152,854

 

Total assets

 

$ 619,581

 

 

$ 603,318

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$ 11,475

 

 

$ -

 

Accounts payable - related parties

 

 

65,506

 

 

 

33,290

 

Contract payable

 

 

100,000

 

 

 

150,000

 

Interest payable to related parties

 

 

50,542

 

 

 

15,220

 

Interest payable

 

 

544

 

 

 

-

 

Convertible promissory note, net of discount of $16,076

 

 

8,924

 

 

 

-

 

Convertible promissory notes payable to related parties, net of discount of $543,319 and $534,519, respectively

 

 

576,681

 

 

 

165,481

 

Total current liabilities

 

 

813,672

 

 

 

363,991

 

Total liabilities

 

 

813,672

 

 

 

363,991

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' equity (deficit)

 

 

 

 

 

 

 

 

Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding

 

 

-

 

 

 

-

 

Common stock: $0.00001 par value; 500,000,000 shares authorized, 74,765,168 and 70,069,693 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively

 

 

749

 

 

 

702

 

Additional paid-in capital

 

 

12,698,944

 

 

 

11,290,209

 

Retained deficit

 

 

(12,893,784 )

 

 

(11,051,584 )

Total stockholders' equity (deficit)

 

 

(194,091 )

 

 

239,327

 

Total liabilities and stockholders' equity (deficit)

 

$ 619,581

 

 

$ 603,318

 

 

(The accompanying notes are an integral part of these consolidated financial statements)

 

 
3
 
Table of Contents

 

RENOVACARE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2017 AND 2016

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

144,885

 

 

 

73,810

 

 

 

223,965

 

 

 

185,632

 

General and administrative

 

 

861,393

 

 

 

453,544

 

 

 

1,164,416

 

 

 

1,122,613

 

Total operating expense

 

 

1,006,278

 

 

 

527,354

 

 

 

1,388,381

 

 

 

1,308,245

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(1,006,278 )

 

 

(527,354 )

 

 

(1,388,381 )

 

 

(1,308,245 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

199

 

 

 

-

 

 

 

457

 

 

 

-

 

Interest expense

 

 

(20,516 )

 

 

-

 

 

 

(35,866 )

 

 

-

 

Accretion of debt discount

 

 

(243,781 )

 

 

-

 

 

 

(418,410 )

 

 

-

 

Total other income (expense)

 

 

(264,098 )

 

 

-

 

 

 

(453,819 )

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$ (1,270,376 )

 

$ (527,354 )

 

$ (1,842,200 )

 

$ (1,308,245 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted Loss per Common Share

 

$ (0.02 )

 

$ (0.01 )

 

$ (0.03 )

 

$ (0.02 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding - basic and diluted

 

 

74,653,184

 

 

 

69,955,847

 

 

 

73,174,724

 

 

 

69,561,676

 

 

(The accompanying notes are an integral part of these consolidated financial statements)

 

 
4
 
Table of Contents

 

RENOVACARE, INC.

 

 

 

 

 

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

FOR THE SIX MONTHS ENDED JUNE 30, 2017 AND YEAR ENDED DECEMBER 31, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Additional

 

 

Retained

 

 

Total Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Paid-in Capital

 

 

Deficit

 

 

Equity (Deficit)

 

Balance, December 31, 2015

 

 

67,781,934

 

 

$ 678

 

 

$ 9,197,970

 

 

$ (8,973,695 )

 

$ 224,953

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-

 

Issuance of common stock from the exercise of warrants

 

 

2,273,913

 

 

 

24

 

 

 

1,109,977

 

 

 

-

 

 

 

1,110,001

 

Issuance of common stock from the exercise of stock options

 

 

13,846

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Stock based compensation due to common stock purchase options

 

 

-

 

 

 

-

 

 

 

296,123

 

 

 

-

 

 

 

296,123

 

Reversal of stock based compensation due to forfeiture of stock options

 

 

-

 

 

 

-

 

 

 

(13,861 )

 

 

-

 

 

 

(13,861 )

Discount on convertible promissory note due to detachable warrants

 

 

-

 

 

 

-

 

 

 

340,735

 

 

 

-

 

 

 

340,735

 

Discount on convertible promissory note due to beneficial conversion feature

 

 

-

 

 

 

-

 

 

 

359,265

 

 

 

-

 

 

 

359,265

 

Net loss for the year ended December 31, 2016

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,077,889 )

 

 

(2,077,889 )

Balance, December 31, 2016

 

 

70,069,693

 

 

 

702

 

 

 

11,290,209

 

 

 

(11,051,584 )

 

 

239,327

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock from the exercise of warrants

 

 

4,592,895

 

 

 

46

 

 

 

344,578

 

 

 

-

 

 

 

344,624

 

Issuance of common stock from the exercise of stock options

 

 

102,580

 

 

 

1

 

 

 

(1 )

 

 

-

 

 

 

-

 

Stock based compensation due to common stock purchase options

 

 

-

 

 

 

-

 

 

 

620,872

 

 

 

-

 

 

 

620,872

 

Discount on convertible promissory note due to detachable warrants and beneficial conversion feature

 

 

-

 

 

 

-

 

 

 

443,286

 

 

 

-

 

 

 

443,286

 

Net loss for the six months ended June 30, 2017

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,842,200 )

 

 

(1,842,200 )

Balance, June 30, 2017 (Unaudited)

 

 

74,765,168

 

 

$ 749

 

 

$ 12,698,944

 

 

$ (12,893,784 )

 

$ (194,091 )

 

(The accompanying notes are an integral part of these consolidated financial statements)

 

 
5
 
Table of Contents

 

RENOVACARE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE SIX MONTHS ENDED JUNE 30, 2017 AND 2016

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2017

 

 

2016

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$ (1,842,200 )

 

$ (1,308,245 )

Adjustments to reconcile net loss to net cash flows from operating activities

 

 

 

 

 

 

 

 

Depreciation

 

 

158

 

 

 

-

 

Stock based compensation expense

 

 

620,872

 

 

 

274,287

 

Accretion of debt discount

 

 

418,410

 

 

 

-

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Decrease (increase) in prepaid expenses

 

 

8,489

 

 

 

(17,687 )

Increase (decrease) in accounts payable

 

 

11,475

 

 

 

9,113

 

Increase (decrease) in accounts payable - related parties

 

 

32,216

 

 

 

(4,160 )

Increase (decrease) in interest payable - related parties

 

 

35,322

 

 

 

-

 

Increase (decrease) in interest payable

 

 

544

 

 

 

-

 

Increase (decrease) in contract payable

 

 

(50,000 )

 

 

(74,750 )

Net cash flows from operating activities

 

 

(764,714 )

 

 

(1,121,442 )

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

Proceeds from exercise of warrants and issuance of common stock

 

 

344,624

 

 

 

1,000,000

 

Proceeds from the issuance of convertible promissory notes

 

 

445,000

 

 

 

-

 

Net cash flows from financing activities

 

 

789,624

 

 

 

1,000,000

 

 

 

 

 

 

 

 

 

 

Increase in cash and cash equivalents

 

 

24,910

 

 

 

(121,442 )

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

 

418,031

 

 

 

397,589

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

$ 442,941

 

 

$ 276,147

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

Interest paid in cash

 

$ -

 

 

$ -

 

Income taxes paid in cash

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of non-cash transactions:

 

 

 

 

 

 

 

 

Discount on convertible promissory note due to detachable warrants and beneficial conversion feature

 

$ 443,286

 

 

$ -

 

 

(The accompanying notes are an integral part of these consolidated financial statements)

 

 
6
 
Table of Contents

 

RENOVACARE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Note 1. Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share

 

Basis of Presentation

 

The unaudited financial statements of RenovaCare, Inc. (the “Company”) as of June 30, 2017, and for the three and six months ended June 30, 2017 and 2016, have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial reporting and include the Company’s wholly-owned subsidiary, RenovaCare Sciences. Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, as filed with the Securities and Exchange Commission as part of the Company’s Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

 

Organization

 

RenovaCare, Inc., together with its wholly owned subsidiary, focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications.

 

On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp., completed the acquisition of its flagship technologies (collectively, the “CellMistTM System”) along with associated United States patent applications and two foreign patent applications, the first of which was filed on August 23, 2007 (DE 10 2007 040 252.1) and the second of which was filed on April 27, 2011 (DE 10 2011 100 450.9), both of which have been granted. One of the US patent applications was granted on November 29, 2016 (Patent No. US 9,505,000) and the other patent application was granted on April 4, 2017 (Patent No. US 9,610,430).

 

The CellMistTM System is comprised of (a) a treatment methodology for cell isolation for the regeneration of human skin cells (the “CellMistTM Solution”) and (b) a solution sprayer device (the “SkinGunTM”) for delivering the cells to the treatment area. The Company has filed additional patent applications related to the CellMistTM Solution and SkinGunTM technologies.

 

Going Concern

 

The Company's activities have consisted principally of performing research and development activities and raising capital. These activities are subject to significant risks and uncertainties, including possible failure of preclinical testing and failing to secure additional funding before achieving sustainable revenue and profit from operations. The Company's ability to fund the development of its cellular therapies will depend on the amount and timing of cash receipts from future financing activities. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business.

 

As of June 30, 2017, the Company has a retained deficit of $12,893,784 and cash and cash equivalents of $442,941. In July 2017, the Company received Private Placement funding of $1.1 million. Based upon its current and near term anticipated level of operations and expenditures, the Company believes that cash on hand should be sufficient to enable it to continue operations through January 2018. If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company’s business, operating results, financial condition and prospects.

 

 
7
 
Table of Contents

 

In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.

 

Recent Accounting Pronouncements

 

Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification.

 

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)”, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC Topic 842, Leases. ASU 2016-02 requires lessees to recognize a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months on its balance sheet. ASU 2016-02 also expands the required quantitative and qualitative disclosures surrounding leases. ASU 2016-02 is effective for the Company beginning January 1, 2019. Early adoption is permitted. The Company has determined that the adoption of ASU 2016-02 will currently have no impact on its consolidated financial statements.

 

In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its consolidated financial statements.

 

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017, and early adoption is permitted. The Company has determined that the adoption of ASU 2014-09 will currently have no impact on its consolidated financial statements.

 

The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements.

 

Earnings (Loss) Per Share

 

The Company presents both basic and diluted earnings per share (“EPS”) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive.

 

 
8
 
Table of Contents

 

Following is the computation of basic and diluted net loss per share for the three and six months ended June 30, 2017 and 2016:

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Basic and Diluted EPS Computation

 

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Loss available to common stockholders'

 

$ (1,270,376 )

 

$ (527,354 )

 

$ (1,842,200 )

 

$ (1,308,245 )

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding

 

 

74,653,184

 

 

 

69,955,847

 

 

 

73,174,724

 

 

 

69,561,676

 

Basic and diluted EPS

 

$ (0.02 )

 

$ (0.01 )

 

$ (0.03 )

 

$ (0.02 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The shares listed below were not included in the computation of diluted losses

per share because to do so would have been antidilutive for the periods presented:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock options

 

 

545,000

 

 

 

437,500

 

 

 

545,000

 

 

 

437,500

 

Warrants

 

 

2,228,908

 

 

 

6,796,087

 

 

 

2,228,908

 

 

 

6,796,087

 

Convertible debt

 

 

633,656

 

 

 

-

 

 

 

633,656

 

 

 

-

 

Total shares not included in the computation of diluted losses per share

 

 

3,407,564

 

 

 

7,233,587

 

 

 

3,407,564

 

 

 

7,233,587

 

 

Note 2. Assets – Intellectual Property

 

On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement (“APA”) with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach’s rights, title and interest in the CellMistTM System. Acquisition related costs amounted to $52,852 and were capitalized together with the cash payment upon the closing of the transaction in July 2013 of $100,002. Intangible assets amounted to $152,854 at June 30, 2017 and December 31, 2016.

 

Note 3. Contract Payable

 

On June 9, 2014, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an amended asset purchase agreement (the “Amended APA”) with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach's rights, title and interest in the CellMist™ System. The Amended APA provided for cash payments of $300,000 as partial consideration for the purchase which are payable as follows: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. At June 30, 2017, $100,000 of the amount payable to Dr. Gerlach was recorded as current liabilities in the accompanying consolidated balance sheet.

 

Note 4. Debt

 

September 9, 2016, $700,000 Convertible Promissory Note

 

On September 9, 2016, the Company entered into a loan agreement (the “Loan Agreement”) with Kalen Capital Corporation (“KCC”); KCC is wholly owned by Mr. Harmel S. Rayat, the Company's majority shareholder. Pursuant to the terms of the Loan Agreement, KCC agreed to loan the Company up to $900,000 at an annual interest rate of 7% per year, compounded quarterly. KCC provided the Company with an initial loan in the amount of $700,000, which was evidenced by a convertible promissory note (the “Note”); the remaining $200,000 may be loaned prior to December 31, 2017, upon the mutual agreement of the Company and KCC. The Note, including any interest due thereon, may be prepaid at any time without penalty. The Note matures on December 31, 2017, and, beginning on the first anniversary of the Note, can be converted, at KCC’s sole discretion, into shares of the Company’s common stock at conversion rate equal to the lesser of: (i) $1.54, or the closing price of the Company’s common stock on the day prior to the issuance of the Note or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23 per share.

 

 
9
 
Table of Contents

 

Per the Loan Agreement, the Company issued KCC a Series E Stock Purchase Warrant (the “Series E Warrant”) to purchase up to 584,416 shares of the Company’s common stock at a purchase price of the lesser of: (i) $1.54, the closing price of the Company’s common stock on the day prior to issuance of the Series E Warrant; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. The Series E Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis.

 

The Loan Agreement provides KCC with registration rights for all of the shares issuable upon conversion of the Note, including conversion of the note issued for the remaining $200,000, if applicable, and exercise of the Series E Warrant, beginning on the first anniversary of the Loan Agreement.

 

The Company calculated the debt discount related to the Note and Series E Warrant by first allocating the respective fair value of the Note and Series E Warrant based upon their relative fair values to the total Note proceeds. The fair value of the Series E Warrant issued with the Note was calculated using the Black-Scholes option pricing model and the following assumptions: exercise price - $1.25 per share; market price of common stock - $1.54 per share; estimated volatility – 92.3%; risk free interest rate - 1.23%; expected dividend rate - 0% and expected life - 5.0 years. The resulting fair value of $340,735 was allocated to the Series E Warrant. The intrinsic value of the beneficial conversion feature amounted to $359,265. The resulting $700,000 discount to the Note is being accreted over the 1.25 year term of the Note.

 

During the three and six months ended June 30, 2017, the Company recognized $12,698 and $25,042 of interest expense and $133,264 and $265,063 of accretion related to the debt discount. The remaining debt discount of $269,456 will be amortized over the next two quarters through December 31, 2017.

 

February 2017, $445,000 Convertible Promissory Notes

 

Between February 23, 2017 and March 9, 2017, the Company entered into three separate loan agreements containing identical terms (the “February 2017 Loan Agreements”) with Joseph Sierchio (“Sierchio”), an investor (the “Investor”) and KCC (collectively, the “Holders”). Pursuant to the terms of the February 2017 Loan Agreements, Sierchio and the Investor each agreed to loan the Company $25,000 and KCC agreed to loan the Company $395,000 at an annual interest rate of 7% per year, compounded quarterly. Each loan was evidenced by a convertible promissory note (collectively, the “February 2017 Notes”). The February 2017 Notes, including any interest due thereon, may not be prepaid without the consent of the Holders. The February 2017 Notes mature on February 23, 2018, and, beginning on the one month anniversary, can be converted, at the Holders’ sole discretion, into shares of the Company’s common stock at conversion rate equal to the lesser of: (i) $3.45, the closing price of the Company’s common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.

 

Per the February 2017 Loan Agreement, the Company issued Sierchio, the Investor and KCC a Series F Stock Purchase Warrant (the “Series F Warrant”) to purchase up to 7,246 shares, 7,246 shares and 114,493 shares, respectively, of the Company’s common stock at an exercise price per share equal to the lesser of: (i) $3.45, the closing price of the Company’s common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. The Series F Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis.

 

The February 2017 Loan Agreements provide the Holders with registration rights for all of the shares issuable upon conversion of the February 2017 Notes, including exercise of the Series F Warrants, beginning on the first anniversary of the February 2017 Loan Agreements.

 

During the three and six months ended June 30, 2017, the Company recognized $7,819 and $10,824 of interest expense and $110,517 and $153,347 of accretion related to the debt discount. The remaining debt discount of $289,939 will be amortized over the next three quarters through March 31, 2018.

 

 
10
 
Table of Contents

 

Note 5. Common Stock and Warrants

 

Common Stock

 

At June 30, 2017, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share, 74,765,168 shares of common stock outstanding and 19,338,572 shares reserved for issuance under the Company’s 2013 Long-Term Incentive Plan (the “2013 Plan”) as adopted and approved by the Company’s Board of Directors (the “Board”) on June 20, 2013 that provides for the grant of stock options to employees, directors, officers and consultants (See “Note 6. Stock Options”).

 

During the six months ended June 30, 2017, the Company had the following common stock related transactions:

 

 

· June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624.

 

 

 

 

· March 1, 2017, KCC exercised 1,326,087 Series B Warrants and 3,500,000 Series C Warrants, on a cashless basis, resulting in the issuance of 4,273,831 shares of common stock.

 

 

 

 

· On February 17, 2017, Thomas Bold, the Company’s President, CEO and Interim Chief Financial Officer exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 34,296 shares of common stock.

 

 

 

 

· On February 10, 2017, Joseph Sierchio, a member of the Company’s board of directors, exercised options to purchase up to 70,000 shares, on a cashless basis, resulting in the issuance of 38,642 shares of common stock.

 

 

 

 

· On February 2, 2017, Kenneth Kirkland, a member of the Company’s board of directors, exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 29,642 shares of common stock.

 

 

 

 

· On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares, on a cashless basis, resulting in the issuance of 204,571 shares of common stock.

 

During the year ended December 31, 2016, the Company had the following common stock related transactions:

 

 

· issued 100,000 shares of common stock, upon the exercise of a Series D Warrant at an exercise price of $1.10 per share resulting in $110,001 of proceeds to the Company.

 

 

 

 

· issued 2,173,913 shares of common stock to KCC on February 2, 2016, upon the exercise of a portion of its Series B Warrant at an exercise price of $0.46 per share resulting in $1,000,000 of proceeds to the Company.

 

 

 

 

· issued 13,846 shares of common stock upon the cashless exercise of an option to purchase 20,000 shares by Joseph Sierchio, a director.

 

Warrants

 

The following table summarizes information about warrants outstanding at June 30, 2017 and December 31, 2016:

 

Shares of Common Stock Issuable from Warrants Outstanding as of

Weighted

Description

June 30,

 

December 31,

Average

Exercise Price

Expiration

2017

2016

Series A

720,000

960,000

$ 0.35

July 12, 2019

Series B

-

1,326,087

$ 0.46

November 29, 2018

Series C

-

3,500,000

$ 0.49

November 29, 2018

Series D

910,000

910,000

$ 1.10

June 5, 2020

Series E

584,416

584,416

$ 1.54

September 8, 2021

Series F

14,492

-

$ 3.45

February 23, 2022 & March 9, 2022

Total

2,228,908

7,280,503

 

 
11
 
Table of Contents

 

As consideration for the CellMistTM System and services performed in connection therewith, the Company issued to Dr. Gerlach a Series A Stock Purchase Warrant entitling him to purchase 1,200,000 shares of the Company’s common stock at an exercise price of $0.35 per share. Pursuant to the terms of the Amended APA, the Series A Warrant will vest in five equal installments of 240,000 shares on each of July 12, 2014, July 12, 2015, July 12, 2016, July 12, 2017 and July 12, 2018. On August 5, 2015, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares on a cashless basis and the Company issued him 196,812 shares of common stock. On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares on a cashless basis and the Company issued him 204,571 shares of common stock.

 

A Series B Warrant with an exercise price of $0.46 to purchase 3,500,000 shares of common stock was issued on November 29, 2013 to KCC in connection with the 11/29 Financing. On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Company’s common stock resulting in proceeds of $1,000,000. On March 1, 2017, KCC exercised, in full, on a cashless basis, the remaining 1,326,087 Series B Warrants resulting in the issuance of 1,181,194 shares of common stock.

 

A Series C Warrant with an exercise price of $0.49, to purchase 3,500,000 shares of common stock was issued on November 29, 2013 to KCC in connection with a financing. On March 1, 2017, KCC exercised, in full, on a cashless basis, the 3,500,000 Series C Warrants resulting in the issuance of 3,092,637 shares of common stock.

 

Series D Warrants with an exercise price of $1.10 to purchase 1,010,000 shares of common stock were issued on June 5, 2015 in connection with the sale of units pursuant to a private placement. On December 6, 2016, a Series D Warrant to purchase shares was exercised resulting in the Company receiving $110,000 of proceeds.

 

A Series E Warrant to purchase 584,416 shares of common stock was issued on September 9, 2016 in connection with the Loan Agreement. The Series E Warrant has an exercise price of the lesser of: (i) $1.54, the closing price of the Company’s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company’s common stock as quoted on the OTCQB for the five days prior to the date on which KCC elects to exercise the Warrant. The Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein.

 

Three Series F Warrants to purchase 128,985 shares of common stock were issued between February 22, 2017 and March 9, 2017 in connection with the February 2017 Loan Agreements. The Series F Warrants have an exercise price of the lesser of: (i) $3.45, the closing price of the Company’s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company’s common stock as quoted on the OTCQB for the five days prior to the date on which the holder elects to exercise the Warrant. The Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein. On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624.

 

Note 6. Stock Options

 

On June 20, 2013, the Company’s Board adopted the 2013 Long-Term Incentive Plan and on November 15, 2013, a stockholder owning a majority of the Company’s issued and outstanding stock approved adoption to the 2013 Plan. Pursuant to the terms of the 2013 Plan, an aggregate of 20,000,000 shares of the Company’s common stock are reserved for issuance to the Company’s officers, directors, employees and consultants in order to attract and hire key technical personnel and management. Options granted to employees under the 2013 Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the 2013 Plan are limited to non-qualified stock options. As of June 30, 2017, there were 19,338,572 shares available for grant.

 

The 2013 Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Company's fiscal year, options to purchase more than 2,000,000 shares under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant.

 

 
12
 
Table of Contents

 

The exercise price per share of common stock for options granted under the 2013 Plan will be the fair market value of the Company's common stock on the date of grant, using the closing price of the Company's common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company's common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the 2013 Plan after June 20, 2023.

 

Stock Option Activity

 

The following table summarizes stock option activity for the six months ended June 30, 2017:

 

 

Number of

Options

 

Weighted

Average

Exercise Price ($)

 

Weighted

Average

Remaining

Contractual Term

 

Aggregate

Intrinsic

Value ($)

Outstanding at December 31, 2015

 

257,500

 

1.07

 

Grants

 

187,500

 

1.92

 

Forfeitures

 

(40,000)

 

1.65

 

Exercises

 

(20,000)

 

0.80

 

Outstanding at December 31, 2016

 

385,000

 

1.42

 

Grants

 

310,000

 

4.20

 

Exercises

 

(150,000)

 

1.12

 

Outstanding at June 30, 2017

 

545,000

 

3.09

 

9.12 years

 

501,425

Exercisable at June 30, 2017

 

375,000

 

2.75

 

8.94 years

 

447,425

Available for grant at June 30, 2017

 

19,338,572

 

The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. There were 310,000 stock options granted during the six months ended June 30, 2017 with a weighted-average grant date fair value of $3.38. There were 180,000 stock options granted during the six months ended June 30, 2016 with a weighted-average grant date fair value of $1.40. There were 150,000 options exercised on a cashless basis resulting in the issuance of 102,582 shares of common stock during the six months ended June 30, 2017, with an aggregate intrinsic value of $397,100. There were no stock options exercised during the six months ended June 30, 2016. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company's historical experience. The risk-free interest rate is based on a U.S. treasury note with maturity similar to the option award's expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below:

 

 

 

2017

 

 

2016

 

Risk-free interest rate

 

1.93% - 2.39

%

 

1.23%- 1.41

%

Expected life in years

 

5.5 - 10.0

 

 

 

5.5

 

Weighted Avg. Expected Volatility

 

98% - 106

%

 

 

92 %

Expected dividend yield

 

 

0

 

 

 

0

 

 

The share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time is expensed ratably over the respective vesting periods. During the three months ended June 30, 2017 and 2016, the Company recognized $617,878 and $1,169, respectively, in share-based compensation. During the six months ended June 30, 2017 and 2016, the Company recognized $620,872 and $274,287, respectively, in share-based compensation. Stock-based compensation has been included in the Consolidated Statement of Operations as follows:

 

 
13
 
Table of Contents

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Research and development

 

$ 64,790

 

 

$ -

 

 

$ 64,790

 

 

$ -

 

General and administrative

 

 

553,088

 

 

 

1,171

 

 

 

556,082

 

 

 

274,287

 

Total

 

$ 617,878

 

 

$ 1,171

 

 

$ 620,872

 

 

$ 274,287

 

 

The following table summarizes information about stock options outstanding and exercisable at June 30, 2017:

 

Stock Options Outstanding

Stock Options Exercisable

Range of

Exercise Prices

Number of Shares Subject to Outstanding Options

Weighted Average Contractual Life (years)

Weighted Average Exercise Price

Number of Shares Subject To Options Exercise

Weighted Average Remaining Contractual

Life (Years)

 

Weighted Average

Exercise Price

0.80

10,000

7.13

0.80

10,000

7.13

0.80

1.05

55,000

6.76

1.05

35,000

6.76

1.05

1.25

7,500

7.96

1.25

7,500

7.96

1.25

1.34

7,500

8.01

1.34

7,500

8.01

1.34

1.65

10,000

8.34

1.65

10,000

8.34

1.65

1.70

7,500

8.30

1.70

7,500

8.30

1.70

1.91

 

130,000

8.71

1.91

130,000

8.71

1.91

2.28

7,500

9.06

2.28

7,500

9.06

2.28

4.20

310,000

9.87

4.20

160,000

9.87

4.20

Total

545,000

9.12

$3.09

375,000

8.94

$2.75

 

Note 7. Commitments

 

Effective March 1, 2015, the Company entered into a lease agreement (the “Lease”) in the Pittsburgh Life Sciences Greenhouse at a monthly rate of $750. The Company has the option to terminate the Lease on the twelve month anniversary of the commencement date, upon one hundred and twenty days’ prior written notice. The Lease was renewed effective March 1, 2017 at a monthly rate of $800.

 

On August 1, 2013, the Company and Vector Asset Management, Inc. (“Vector”) entered into a Consulting Agreement whereby Vector will assist the Company with identifying subject matter experts in the medical device and biotechnology industries and to assist the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology (collectively, the “Services”). On May 1, 2016, Vector and the Company entered into an amendment to the consulting agreement. Pursuant to the amendment, the term of the agreement terminates only upon written notice, and the monthly consulting fee, in consideration of the Services, was increased to $6,800 from $5,000. No other changes were made to the agreement.

 

In connection with the Company’s anticipated regulatory filings, the Company has engaged StemCell Systems GmbH (“StemCell Systems”) to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $52,830 and $36,000 during the three months ended June 30, 2017 and 2016, respectively, and $106,830 and $110,567 during the six months ended June 30, 2017 and 2016, respectively. Dr. Gerlach, from whom the Company purchased the CellMistTM System technologies, is a principal of StemCell Systems.

 

See also “Note 8. Related Party Transactions.”

 

 
14
 
Table of Contents

 

Note 8. Related Party Transactions

 

As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio will receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service. Additionally, on March 15, 2016, the Company granted to each of Dr. Kirkland and Mr. Sierchio an incentive stock option to purchase up to 50,000 shares of the Company’s common stock at an exercise price of $1.91 per share. The options became fully vested upon grant. On May 11, 2017, the Company granted to each of Dr. Kirkland and Mr. Sierchio an incentive stock option to purchase up to 75,000 shares of the Company’s common stock at an exercise price of $4.20 per share. 37,500 of the May 11 grant vested immediately with the remaining 37,500 vesting in one year on May 11, 2018. The option strike prices equal the closing price of the Company’s common stock on the day of grant. The Options may be exercised on a “cashless basis” using the formula contained therein.

 

The law firm of Sierchio & Partners, LLP, of which Joseph Sierchio, one of the Company’s directors, was a principal, has provided counsel to the Company since August 26, 2010 and beginning in September 2016, Mr. Sierchio became a partner at Satterlee Stephens LLP (“Satterlee”). Concurrently with Mr. Sierchio’s move to Satterlee, the Company engaged wih Satterlee to provide legal counsel with Mr. Sierchio maintaining his role as the Company’s primary attorney. During the three months ended June 30, 2017 and 2016, the Company recognized $77,537 and $54,665 of fees for legal services billed by firms associated with Mr. Sierchio. During the six months ended June 30, 2017 and 2016, the Company recognized $180,668 and $91,515 of fees for legal services billed by firms associated with Mr. Sierchio. Included in accounts payable, at June 30, 2017 and December 31, 2016, is $40,000 and $11,750, respectively, owed to Satterlee. Mr. Sierchio continues his role with the Company as a director.

 

In connection with the Company’s anticipated regulatory filings, the Company has engaged StemCell Systems to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $52,830 and $36,000 during the three months ended June 30, 2017 and 2016, respectively, and $106,830 and $110,567 during the six months ended June 30, 2017 and 2016, respectively. Dr. Gerlach, from whom the Company purchased the CellMistTM System technologies, is a principal of StemCell Systems.

 

On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University, pursuant to which the Company committed to provide a charitable donation to the University in the aggregate amount of $75,000. The Company paid the Grant in eight quarterly installments of $9,375, with the final payment made on July 22, 2016. Dr. Gerlach, from whom the Company purchased the CellMistTM System technologies, is a professor at the University.

 

Dr. Gerlach is entitled to payments for consulting services. During the three months ended June 30, 2017 and 2016, the Company recognized expenses related to Dr. Gerlach services of $8,460 and $12,060, respectively. During the Six months ended June 30, 2017 and 2016, the Company recognized expenses related to Dr. Gerlach services of $18,540 and $23,940, respectively. Accounts payable to Dr. Gerlach amounted to $8,460 and $18,540 at June 30, 2017 and December 31, 2016, respectively.

 

On May 1, 2015, the Company entered into the Option Agreement with Dr. Gerlach, pursuant to which the Company obtained a one-year exclusive option to evaluate the Technology, for the purpose of determining whether the Company would like to purchase or license the Technology. Pursuant to the terms of the Option Agreement, the Company paid Dr. Gerlach a non-refundable fee of $24,000, payable in four quarterly installments of $6,000, with the first installment due on May 1, 2015. The entire $24,000 option payment was recognized as research and development expense during the period ended December 31, 2015. The final $6,000 payment was made on February 1, 2016.

 

On September 9, 2016, the Company entered into the Loan Agreement with KCC whereby KCC agreed to loan the Company up to $900,000 at an interest rate of 7%. KCC provided the Company with an initial loan of $700,000; the remaining $200,000 may be loaned prior to December 31, 2017. The Note matures on December 31, 2017, and, beginning on the first anniversary of the Note, can be converted into shares of the Company’s common stock at conversion rate equal to the lesser of: (i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23.

 

Per the Loan Agreement, the Company issued KCC a Series E Warrant to purchase up to 584,416 shares of the Company’s common stock at a purchase price of the lesser of: (i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. The Series E Warrant is exercisable for a period of five years and may be exercised on a cashless basis, See “Note 4. Debt” for additional disclosure.

 

 
15
 
Table of Contents

 

On February 23, 2017, the Company entered into two of the February 2017 Loan Agreements with Sierchio and KCC pursuant to which Sierchio loaned the Company $25,000 and KCC loaned $395,000 at an interest rate of 7%. The February 2017 Notes mature on February 23, 2018, and, beginning on the one month anniversary, can be converted into shares of the Company’s common stock at conversion rate equal to the lesser of: (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.

 

Per the February 2017 Loan Agreement, the Company issued Sierchio, and KCC a Series F Warrant to purchase up to 7,246 shares and 114,493 shares, respectively, of the Company’s common stock at an exercise per share equal to the lesser of: (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. The Series F Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis. See “Note 4. Debt” for additional disclosure.

 

On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624.

 

March 1, 2017, KCC exercised 1,326,087 Series B Warrants and 3,092,637 Series C Warrants, on a cashless basis, resulting in the issuance of 4,273,831 shares of common stock.

 

On February 17, 2017, Thomas Bold, the Company’s President, CEO and Interim Chief Financial Officer exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 34,296 shares of common stock.

 

On February 10, 2017, Joseph Sierchio, a member of the Company’s board of directors, exercised options to purchase up to 70,000 shares, on a cashless basis, resulting in the issuance of 38,642 shares of common stock.

 

On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Company’s common stock at an exercise price of $0.46 per share resulting in proceeds of $1,000,000.

 

On February 2, 2017, Kenneth Kirkland, a member of the Company’s board of directors, exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 29,642 shares of common stock.

 

On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares, on a cashless basis, resulting in the issuance of 204,571 shares of common stock.

 

Note 9. Subsequent Events

 

On July 21, 2017, the Company completed a self-directed offering of 460,250 units of the Company's equity securities (the "Units") at a price of $2.44 per unit for $1,123,010 in aggregate proceeds (the “July 2017 Private Placement”). Each unit consists of (a) one share of common stock and one Series G Stock Purchase Warrant (the “Series G Warrants”) allowing the holder to purchase one (1) share of the Company’s common stock at a price of $2.68 per share for a period of five years. The warrants may be exercised on a cashless basis. Of the 460,250 Units purchased, KCC purchased 410,000.

 

The relative fair value of the common stock was estimated to be $635,010. The relative fair value of the Series G Warrants was estimated to be $488,000 as determined based on the relative fair value allocation of the proceeds received. The Series G Warrants were valued using the Black-Scholes option pricing model using the following variables: market price of common stock - $2.92 per share; estimated volatility – 102.23%; 5-year risk free interest rate – 1.81%; expected dividend rate - 0% and expected life - 5 years.

 

The Company intends to use the proceeds from the July 2017 Private Placement for general corporate purposes, including the continued research and development of the Company’s SkinGunTM and CellMistTM technologies and for working capital.

 

The July 2017 Private Placement was conducted pursuant to exemptions from the registration requirements afforded by, among others, Rule 506(c) of Regulation D ("Regulation D") and Regulation S ("Regulation S"), as promulgated under the Securities Act of 1933, as amended. Accordingly, the Offering was available only to investors who reasonably verify to the Company that they are "accredited investors," as such term is defined in Rule 501(a) of Regulation D or who are not U.S. Persons, as such term is defined in Rule 902 of Regulation S.

 

 
16
 
Table of Contents

 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Quarterly Report filed on Form 10-Q. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors.

 

This discussion and analysis should be read in conjunction with the accompanying unaudited interim consolidated financial statements and related notes. The discussion and analysis of the financial condition and results of operations are based upon the unaudited interim consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis we review our estimates and assumptions. The estimates were based on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Critical accounting policies, the policies us believes are most important to the presentation of its financial statements and require the most difficult, subjective and complex judgments, are outlined below in "Critical Accounting Policies," and have not changed significantly.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as information relating to RenovaCare, Inc. and its subsidiaries that is based on management's exercise of business judgment and assumptions made by and information currently available to management. Although forward-looking statements in this Quarterly Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. When used in this document and other documents, releases and reports released by us, the words "anticipate," "believe," "estimate," "expect," "intend," "the facts suggest" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect our current view of future events and are subject to certain risks and uncertainties as noted below. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results could differ materially from those anticipated in these forward-looking statements. Actual events, transactions and results may materially differ from the anticipated events, transactions or results described in such statements. Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Many factors could cause actual results to differ materially from our forward looking statements and unknown, unidentified or unpredictable factors could materially and adversely impact our future results. We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions to our forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events. Several of these factors include, without limitation:

 

·

our ability to meet requisite regulations or receive regulatory approvals in the United States, and our ability to retain any regulatory approvals that we may obtain; and the absence of adverse regulatory developments in the United States and abroad;

·

new entrance of competitive products or further penetration of existing products in our markets;

·

the effect on us from adverse publicity related to our products or the company itself; and

·

any adverse claims relating to our intellectual property.

 

 
17
 
Table of Contents

 

The safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, apply to forward-looking statements made by us. The reader is cautioned that no statements contained in this Form 10-Q should be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks described in this report and matters described in this report generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur.

 

Overview

 

RenovaCare, Inc. (formerly Janus Resources, Inc.) (together with its wholly owned subsidiary, “RenovaCare” the “Company” “we” “us” and “our”) was incorporated under the laws of the State of Nevada and has an authorized capital of 500,000,000 shares of $0.00001 par value common stock, of which 75,225,418 shares are outstanding as of August 8, 2017, and 10,000,000 shares of $0.0001 par value preferred stock, of which none are outstanding.

 

On January 7, 2014, we filed a Certificate of Amendment to Articles of Incorporation changing our name from “Janus Resources, Inc.” to “RenovaCare, Inc.” so as to more fully reflect our operations. The Financial Industry Regulatory Authority (“FINRA”) declared the name change effective as of January 9, 2014. In conjunction with the name change, we changed our stock symbol on the OTCQB from “JANI” to “RCAR”.

 

Our principal executive offices are located at 430 Park Avenue, Suite 702, New York, NY 10022. Our telephone number is (888) 398-0202.

 

As we are a smaller reporting company, we are not required to make certain disclosures otherwise required to be made in a Form 10-Q.

 

Description of Business

 

We are a development-stage company focusing on the acquisition, development and commercialization of autologous (using a patient’s own cells) cellular therapies for medical and aesthetic applications. On July 12, 2013, we, through our wholly owned subsidiary, RenovaCare Sciences Corp., completed the acquisition of our flagship technologies (collectively, the “CellMistTM System”) along with associated United States patent applications and two foreign patent applications, the first of which was filed on August 23, 2007 (DE 10 2007 040 252.1) and the second of which was filed on April 27, 2011 (DE 10 2011 100 450.9), both of which have been granted. One of the US patent applications was granted to us on November 29, 2016 (Patent No. US 9,505,000) and the other patent application was granted to us on April 4, 2017 (Patent No. US 9,610,430). In the case of U.S. patents, a typical utility patent term is 20 years from the date on which the application for the patent was filed in the United States or, if the application contains a specific reference to an earlier filed application or applications, from the date on which the earliest such application was filed. Patents filed outside of the U.S. have a patent term typically running 20 years from the date of first filing, but which are determined by the law of the country in which they issue. Patent term may be affected by events such as maintenance (or annuity) fee payment, terminal or statutory disclaimer, post-grant proceedings, patent term adjustment, and/or patent term extension.

 

The CellMistTM System is comprised of (a) a treatment methodology for cell isolation for the regeneration of human skin cells (the “CellMistTM Solution”) and (b) a solution sprayer device (the “SkinGunTM”) for delivering the cells to the treatment area. We have filed additional patent applications related to the CellMistTM Solution and SkinGunTM technologies.

 

We effected the acquisition of the CellMistTM System through an asset purchase agreement with Dr. Jorg Gerlach, MD, PhD (the “APA”). Pursuant to the terms of the APA, as amended on September 9, 2014, we paid Dr. Gerlach an initial sum of $100,000 and are obligated to pay him an additional $300,000 in four installments: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. Additionally, we issued to Dr. Gerlach a Series A Warrant allowing him to purchase up to 1,200,000 shares of our common stock at a purchase price of $0.35 per share through July 12, 2019; the warrant vests in five equal annual installments.

 

 
18
 
Table of Contents

 

The average adult human has a skin surface area of between 16 - 21 square feet, which protects all other organs against the external environment. When a person’s skin is assailed by trauma or exposed to extreme heat, the skin's various layers may be destroyed and, depending on the severity of the injury, might cause life-threatening conditions. Currently, severe trauma to the skin, such as second or third degree burns, requires surgical mesh-grafting of skin, whereby healthy skin is removed from one area of the patient's body (a “donor site”) and implanted on the damaged area. While mesh grafting is often the method of choice, we believe there are significant deficiencies with this method. The surgical procedure to remove healthy skin from the donor site can be painful and leaves the patient with a new wound that must also be attended to. In many instances the aesthetic results are not satisfying, as the color of the skin from the donor site may not match the skin color of the damaged skin. Additionally, since the ratio between the size of the wound area and the size of the donor site is quite low, i.e. the size of the skin removed must be substantially equal in size to the size of the damaged skin, the mesh-grafting approach is in many cases limited. Donor and injury sites can take weeks to heal, requiring expensive hospital stays, ongoing wound dressing management, and ever-changing anti-infection strategies. We are currently evaluating the efficacy and potential of our SkinGunTM, in combination with our CellMist™ Solution, in the treatment of tissue that has been subject to severe trauma such as second and third degree burns. In small scale clinical trials, the CellMistTM System has shown the ability to regenerate a more natural and thicker skin. The CellMistTM System utilizes the patient’s own skin stem cells and is able to address much larger treatment areas and at the same time reduce the size of the donor site. Furthermore, we believe the CellMistTM System enables the effective treatment of other skin disorders with minimal scarring compared to skin grafting.

 

In a clinical study of 19 patients with deep dermal wound burns to the face and neck conducted in Berlin, Germany prior to our purchase of the CellMist™ System, researchers stated that, “careful surgical debridement and consecutive application of CEA [cultured epithelial auto graft] suspensions using a spray technique results in excellent cosmetic outcomes compared with any other method.” The same researchers concluded that, “We refuse to perform a prospective randomized study with groups in which traditional skin grafting and/or wound healing are still applied for the therapy for deep dermal burns due to the excellent results in our study. The method of CEA spray application has become our standard of care for these indications. The faster wound closure, the promotion of spontaneous wound healing by keratinocyte application, as well as the preservation of donor sites are further advantages of the method.” (Hartmann MD, Bernd, et al, “Sprayed Cultured Epithelial Autografts for Deep Dermal Burns of the Face and Neck” Annals of Plastic Surgery, 58.1(2007): 70-73. Print. emphasis added). The CEA spray application used by the researchers in the publication refers to earlier iterations of what is now CellMistTM System . Dr. Gerlach, from whom we purchased the CellMistTM System, assisted in the study.

 

The development of our CellMist™ System is in the early stage and we anticipate that we will be required to expend significant time and resources to further develop our technology and determine whether a commercially viable product can be developed. Research and development of new technologies involves a high degree of risk and there is no assurance that our development activities will result in a commercially viable product. The long-term profitability of our operations will be, in part, directly related to the cost and success of our development programs, which may be affected by a number of factors.

 

Intellectual Property

 

General

 

In the course of conducting our business, we from time to time create inventions. Obtaining, maintaining and protecting our inventions, including seeking patent protection, might be important depending on the nature of the invention. To that end, we seek to implement patent and other intellectual property strategies to appropriately protect our intellectual property. While we file and prosecute patent applications to protect our inventions, our pending patent applications might not result in the issuance of patents or issued patents might not provide competitive advantages. Also, our patent protection might not prevent others from developing competitive products using related or other technology.

 

 
19
 
Table of Contents

 

The scope, enforceability and effective term of issued patents can be highly uncertain and often involve complex legal and factual questions. Moreover, the issuance of a patent in one country does not assure the issuance of a patent with similar claim scope in another country, and claim interpretation and infringement laws vary among countries, so we are unable to predict the extent of patent protection in any country. The patents we obtain and the unpatented proprietary technology we hold might not afford us significant commercial protection or advantage.

 

In addition to issued patents describe above, we plan to file additional patent applications that, if issued, would provide further protection for The CellMistTM System. Although we believe the bases for these patents and patent applications are sound, they are untested; and there is no assurance that they will not be successfully challenged. There can be no assurance that any patent previously issued will be of commercial value, that any patent applications will result in issued patents of commercial value, or that our technology will not be held to infringe patents held by others.

 

Strategy

 

Our ultimate goal is to leverage the potential of our CellMist™ System as cutting edge treatments in skin therapy. Before we can do so, however, there are a number of steps we must first take, including:

 

·

initiating a series of clinical trials to determine the CellMist™ System's safety and efficacy for treating wounds and burns;

·

formalizing collaborations with universities and scientific partners;

·

creating a network of clinical and research partners; and

·

achieving Food and Drug Administration (the "FDA") and other regulatory clearance.

 

Additionally, we will likely be required to raise significant capital in order to fund our ongoing research and development operations, and there is no guarantee that we will be able to raise capital on acceptable terms, if at all.

 

Results of Operations

 

Three and Six Months Ended June 30, 2017 Compared with the Three and Six Months Ended June 30, 2016

 

Operating Expenses

 

A summary of our operating expense for the three and six months ended June 30, 2017 and 2016 follows:

 

 

 

Three Months Ended June 30,

 

 

Increase /

 

 

Percentage

 

 

 

2017

 

 

2016

 

 

(Decrease)

 

 

Change

 

Operating expense

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$ 80,095

 

 

$ 73,810

 

 

$ 6,285

 

 

 

9 %

General and administrative

 

 

308,305

 

 

 

452,373

 

 

 

(144,068 )

 

 

-32

%

Stock compensation

 

 

617,878

 

 

 

1,171

 

 

 

616,707

 

 

nmf

 

Total operating expense

 

$ 1,006,278

 

 

$ 527,354

 

 

$ 478,924

 

 

 

91 %

 

 

 

Six Months Ended June 30,

 

 

Increase /

 

 

Percentage

 

 

 

2017

 

 

2016

 

 

(Decrease)

 

 

Change

 

Operating expense

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$ 159,175

 

 

$ 185,632

 

 

$ (26,457 )

 

 

-14

%

General and administrative

 

 

608,334

 

 

 

848,326

 

 

 

(239,992 )

 

 

-28

%

Stock compensation

 

 

620,872

 

 

 

274,287

 

 

 

346,585

 

 

 

126 %

Total operating expense

 

$ 1,388,381

 

 

$ 1,308,245

 

 

$ 80,136

 

 

 

6 %

 

Research and Development

 

Research and development (“R&D”) costs represent costs incurred to develop our CellMistTM System and are incurred pursuant to agreements with third party providers and certain internal R&D cost allocations. Payments under these agreements include salaries and benefits for R&D personnel, allocated overhead, contract services and other costs. R&D costs are expensed when incurred. R&D costs increased during the three months and decreased during the six months ended June 30, 2017 compared to 2016, as a result of the timing of certain of our R&D expenses; we anticipate that R&D expenses will increase towards the middle and end of 2017.

 

 
20
 
Table of Contents

 

General and Administrative

 

General and administrative costs include all expenditures incurred other than research and development related costs, including costs related to personnel, professional fees, travel and entertainment, public company costs, insurance and other office related costs. General and administrative costs, excluding stock based compensation, decreased during the three and six months ended June 30, 2017 compared to 2016 due primarily to a decrease in investor communications related fees, lower personnel costs and lower travel costs offset by higher professional fees.

 

Stock Compensation

 

Expense associated with equity based transactions is calculated and expensed in our financial statements as required pursuant to various accounting rules and is non-cash in nature. Stock compensation represents the expense associated with the amortization of our stock options. Stock compensation expense increased during the three and six months ended June 30, 2017 compared to the three and six months ended June 30, 2016 due to the May 11, 2017 grant of 310,000 stock options of which 160,000 vested on the date of grant whereas no stock options were granted during the second quarter of 2016.

 

Other Income (Expense)

 

Other income relates to interest earned on bank account deposits. Other expense relates to our convertible promissory notes. Interest expense relates to the stated interest of the convertible promissory notes. Accretion of debt discount represents the accretion of the discount applied to the notes as a result of the issuance of detachable warrants and the beneficial conversion feature contained in the notes.

 

Liquidity and Capital Resources

 

We currently finance our activities through the sale of our equity securities and issuance of debt. There is no assurance that funding will be accessible to us at the times and in the amounts required to fund our ongoing operations. There are many conditions beyond our control, which have a direct bearing on the level of investor interest in the purchase of our securities. We do not have any agreements or understandings with any person as to additional financing. At June 30, 2017, we had cash of $442,941, negative working capital of $347,685 and total liabilities of $813,672. Subsequent to our quarter end, on July 21, 2017, the Company closed a financing that resulted in $1,123,010 of proceeds to the Company.

 

Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America and applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As discussed in Note 1 to the consolidated financial statements, we have incurred recurring operating losses since inception of $12,893,784. We require additional funds to meet our obligations and maintain our operations. Management believes that the Company's cash and cash equivalent balances will be sufficient to meet the Company's cash requirements through January 2018. We do not currently have cash flow from operations as we have no commercialized products; without cash flow from operations, we will need to obtain additional funds (presumably through equity offerings, debt borrowing or through the exercise of outstanding warrants, which, if exercised in total for cash would result in proceeds of $3,436,000; all of our outstanding warrants currently include a “cashless exercise” feature) in order to implement our current research and development programs for the CellMistTM System. If we are unable to obtain adequate funds, or if such funds are not available to us on acceptable terms, our ability to continue our business as planned will be significantly impaired and it may cause us to curtail operations.

 

Net cash used in operating activities was $764,714 during the six months ended June 30, 2017, compared to net cash used in operating activities of $1,121,442 during the six months ended June 30, 2016. The decrease in cash used in operating activities is due to fewer dollars spent on public and investors relations, personnel compensation and R&D offset by higher professional fees.

 

 
21
 
Table of Contents

 

Net cash provided by financing activities was $789,624 during the six months ended June 30, 2017, compared to $1,000,000 during the six months ended June 30, 2016.

 

On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624.

 

On February 23, 2017 and March 9, 2017, we entered into loan agreements with KCC, Sierchio and an Investor whereby KCC, Sierchio and an Investor loaned us $395,000, $25,000 and $25,000, respectively.

 

On September 9, 2016, we entered into a loan agreement with KCC whereby KCC agreed to loan us up to $900,000 with an initial loan in the amount of $700,000.

 

On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of our common stock at an exercise price of $0.46 per share resulting in proceeds of $1,000,000.

 

Off-balance Sheet Arrangements and Contractual Obligations

 

We do not have any off-balance sheet arrangements or contractual obligations at June 30, 2017, and the subsequent period to through the date of this report, that are likely to have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that have not been disclosed in our consolidated financial statements.

 

Recently Issued Accounting Pronouncements

 

See Note 1 to our Consolidated Financial Statements for more information regarding recent accounting pronouncements and their impact to our consolidated results of operations and financial position.

 

Related Party Transactions

 

Our proposed business raises potential conflicts of interests between certain of our officers and directors and us. Certain of our directors are employees or consultants to other companies in the healthcare industry and, to the extent that such other companies may participate in ventures in which we may participate, our directors may have a conflict of interest in negotiating and concluding terms regarding the extent of such participation. In the event that such a conflict of interest arises at a meeting of our directors, a director who has such a conflict will abstain from voting for or against the approval of such participation or such terms. Other than as indicated, we have no other procedures or mechanisms to deal with conflicts of interest. We are not aware of the existence of any conflict of interest as described herein.

 

Other than as disclosed below, during the three and six months ended June 30, 2017 and 2016, and the subsequent period, none of our current directors, officers or principal shareholders, nor any family member of the foregoing, nor, to the best of our information and belief, any of our former directors, senior officers or principal shareholders, nor any family member of such former directors, officers or principal shareholders, has or had any material interest, direct or indirect, in any transaction, or in any proposed transaction which has materially affected or will materially affect us.

 

As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service. For the three months ended June 30, 2017, directors' and consulting fees with respect to our officers and directors were $3,000 (2016: $3,000). For the six months ended June 30, 2017, directors' and consulting fees with respect to our officers and directors were $6,000 (2016: $6,000).

 

 
22
 
Table of Contents

 

The law firm of Sierchio & Partners, LLP, of which Joseph Sierchio, one of the Company’s directors, was a principal, has provided counsel to the Company since August 26, 2010 and beginning in September 2016, Mr. Sierchio became a partner at Satterlee. Concurrently with Mr. Sierchio’s move to Satterlee, the Company engaged wih Satterlee to provide legal counsel with Mr. Sierchio maintaining his role as the Company’s primary attorney. During the three months ended June 30, 2017 and 2016, the Company recognized $77,537 and $54,665 of fees for legal services billed by firms associated with Mr. Sierchio. During the six months ended June 30, 2017 and 2016, the Company recognized $180,668 and $91,515 of fees for legal services billed by firms associated with Mr. Sierchio. Included in accounts payable, at June 30, 2017 and December 31, 2016, is $40,000 and $11,750, respectively, owed to Satterlee. Mr. Sierchio continues his role with the Company as a director.

 

In connection with the Company’s anticipated regulatory filings, the Company has engaged StemCell Systems to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $52,830 and $36,000 during the three months ended June 30, 2017 and 2016, respectively, and $106,830 and $110,567 during the six months ended June 30, 2017 and 2016, respectively. Dr. Gerlach, from whom the Company purchased the CellMistTM System technologies, is a principal of StemCell Systems.

 

On September 25, 2014, we entered into a Charitable Grant Agreement with the University, pursuant to which we committed to provide a charitable donation to the University in the aggregate amount of $75,000. We paid the Grant in eight quarterly installments of $9,375, with the final payment made on July 22, 2016. Dr. Gerlach, from whom we purchased the CellMistTM System technologies, is a professor at the University.

 

Dr. Gerlach is entitled to payments for consulting services. During the three months ended June 30, 2017 and 2016, the Company recognized expenses related to Dr. Gerlach services of $8,460 and $12,060, respectively. During the Six months ended June 30, 2017 and 2016, the Company recognized expenses related to Dr. Gerlach services of $18,540 and $23,940, respectively. Accounts payable to Dr. Gerlach amounted to $8,460 and $18,540 at June 30, 2017 and December 31, 2016, respectively.

 

On May 1, 2015, we entered into the Option Agreement with Dr. Gerlach, pursuant to which we obtained a one-year exclusive option to evaluate the Technology, for the purpose of determining whether we would like to purchase or license the Technology. Pursuant to the terms of the Option Agreement, we paid Dr. Gerlach a non-refundable fee of $24,000, payable in four quarterly installments of $6,000, with the first installment due on May 1, 2015. The entire $24,000 option payment was recognized as research and development expense during the period ended December 31, 2015. The final $6,000 payment was made on February 1, 2016.

 

On September 9, 2016, we entered into a loan agreement with KCC. Pursuant to the terms of the Loan Agreement, KCC agreed to loan us up to $900,000 at an annual interest rate of 7% per year, compounded quarterly. KCC provided us with an initial loan in the amount of $700,000, which was evidenced by the Note; the remaining $200,000 may be loaned prior to December 31, 2017, upon the mutual agreement of us and KCC. The Note, including any interest due thereon, may be prepaid at any time without penalty. The Note matures on December 31, 2017, and, beginning on the first anniversary of the Note, can be converted, at KCC’s sole discretion, into shares of our common stock at conversion rate equal to the lesser of: (i) $1.54, or the closing price of our common stock on the day prior to the issuance of the Note or (ii) a 20% discount to the average closing price of our common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23.

 

Per the Loan Agreement, we issued KCC a Series E Warrant to purchase up to 584,416 shares of our common stock at a purchase price of the lesser of: (i) $1.54, the closing price of our common stock on the day prior to issuance of the Series E Warrant; or (ii) a 20% discount to the average closing price of our common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. The Series E Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis.

 

 
23
 
Table of Contents

 

On February 23, 2017, we entered into two the February 2017 Loan Agreements with Joseph Sierchio, a member of our board of directors (“Sierchio”) and Kalen Capital Corporation, which is wholly owned by Mr. Harmel S. Rayat, our majority shareholder (“KCC” and together with Sierchio, the “Holders”). Pursuant to the terms of the February 2017 Loan Agreements, Sierchio loaned us $25,000 and KCC loaned $395,000 at an annual interest rate of 7% per year, compounded quarterly. Each loan was evidenced by a convertible promissory note (collectively, the “February 2017 Notes”). The February 2017 Notes, including any interest due thereon, may not be prepaid without the consent of the Holders. The February 2017 Notes mature on February 23, 2018, and, beginning on the one month anniversary, can be converted, at the Holders’ sole discretion, into shares of our common stock at conversion rate equal to the lesser of: (i) $3.45, the closing price of our common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of our common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.

 

Per the February 2017 Loan Agreement, we issued Sierchio and KCC a Series F Warrant to purchase up to 7,246 shares and 114,493 shares, respectively, of our common stock at an exercise per share equal to the lesser of: (i) $3.45, the closing price of our common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of our common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. The Series F Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis.

 

On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624.

 

March 1, 2017, KCC exercised 1,326,087 Series B Warrants and 3,092,637 Series C Warrants, on a cashless basis, resulting in the issuance of 4,273,831 shares of common stock.

 

On February 17, 2017, Thomas Bold, the Company’s President, CEO and Interim Chief Financial Officer exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 34,296 shares of common stock.

 

On February 10, 2017, Joseph Sierchio, a member of the Company’s board of directors, exercised options to purchase up to 70,000 shares, on a cashless basis, resulting in the issuance of 38,642 shares of common stock.

 

On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Company’s common stock at an exercise price of $0.46 per share resulting in proceeds of $1,000,000.

 

On February 2, 2017, Kenneth Kirkland, a member of the Company’s board of directors, exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 29,642 shares of common stock.

 

On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares, on a cashless basis, resulting in the issuance of 204,571 shares of common stock.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

At the end of the period covered by this Quarterly Report on Form 10-Q for the three month period ended June 30, 2017, an evaluation was carried out under the supervision of and with the participation of our management, including the Chief Executive Officer ("CEO") of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). Based on that evaluation the CEO has concluded that as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that: (i) information required to be disclosed by us in reports that we file or submit to the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in applicable rules and forms and (ii) material information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our CEO, as appropriate, to allow for accurate and timely decisions regarding required disclosure.

 

Changes in Internal Control over Financial Reporting

 

During the period covered by this report, there were no changes to internal control over financial reporting that materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

 
24
 
Table of Contents

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

 

On April 4, 2017, the U.S. Patent & Trademark Office (the “PTO”) issued to the Company U.S. Patent No. 9,610,430 related to its device and method for spraying autologous skin cells. On or about April 11, 2017, the Company received from Avita Medical Limited (“Avita”) a paper copy of what was labeled a Petition for Inter Partes Review purporting to challenge the validity of the claims in U.S. Patent No. 9,610,430 (the “Petition”) before the Patent Trial and Appeal Board (“PTAB”), which is an administrative proceeding of the PTO (the “Proceeding”). The Company does not agree with the assertions set forth in the Petition and intends to defend its intellectual property.

 

In the event the Proceeding progresses, the PTAB may find (i) that the Petition is insufficient to establish that any such claims are unpatentable and accordingly confirm all of the claims in the Company’s U.S. Patent No. 9,610,430 or (ii) one or more claims of U.S. Patent No. 9,610,430 to be unpatentable and cancel any such claims and confirm the balance of such claims.

 

Item 1A. Risk Factors

 

Smaller reporting companies are not required to provide the information required by this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

On February 23, 2017, the Company entered into loan agreements (collectively, the “Loan Agreements”) with each of Kalen Capital Corporation (“KCC”), a private company that owns in excess of 10% of the Company’s common stock and Joseph Sierchio (“Sierchio”), a member of the Company’s Board of Directors (together with KCC, the “Investors”). Pursuant to the terms of the Loan Agreements, the Investors agreed to loan the Company a total of $420,000 ($395,000 by KCC and $25,000 by Sierchio) at an annual interest rate of 7% per year, compounded quarterly, which was evidenced by convertible promissory notes (collectively, the “Notes”).

 

The Notes mature on February 23, 2018, and, beginning one month from their issuance, may be converted, at the Investors’ sole discretion, into shares of the Company’s common stock at a conversion price equal to the lesser of: (i) $3.45, the closing price of the Company’s common stock as quoted on the OTC Markets Group Inc. QB tier (the “OTCQB”) on the day prior to the issuance of the Notes or (ii) a twenty percent (20%) discount to the average closing price of the Company’s common stock as quoted on the OTCQB for the five (5) days prior to the date on which the Investors elect to convert their respective Note. The Notes, including any interest due thereon, may not be prepaid without the Investors’ consent.

 

Per the Loan Agreements, the Company issued the Investors Series F Stock Purchase Warrants (collectively, the “Warrants”) to purchase up to an aggregate of 121,739 shares of the Company’s common stock (a Warrant to purchase up to 114,493 shares for KCC and a Warrant to purchase up to 7,246 shares for Sierchio) at an exercise price of the lesser of: (i) $3.45, the closing price of the Company’s common stock as quoted on the OTCQB on the day prior to issuance of the Warrants; or (ii) a twenty percent (20%) discount to the average closing price of the Company’s common stock as quoted on the OTCQB for the five (5) days prior to the date on which the Investors elect to exercise their respective Warrant, subject to a floor of $2.76. The Warrants are exercisable for a period of five (5) years from the date of issuance and may be exercised on a cashless basis using the formula contained therein. The Warrants are exercisable beginning one month from their issuance.

 

The Loan Agreements provide the Investors with registration rights for all of the shares issuable upon conversion of the Notes and exercise of the Warrants.

 

The offer and sale of the Notes and Warrants was completed pursuant to the exemptions from registration provided by, among others, Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and the provisions of Regulation D and Regulation S as promulgated under the Securities Act. The Company intends to use the proceeds of the Notes for working capital and general corporate purposes.

 

 
25
 
Table of Contents

 

Item 6. Exhibits

 

Exhibit No.

Description of Exhibit

3.1

Articles of Incorporation, as amended, of the Company, incorporated by reference and included in the Company’s Registration Statement on Form 10-SB 12g filed on May 11, 1999, SEC file number 000-30156-99616992.

3.2

Articles of Incorporation, as amended, of the Company incorporated by reference and included in the Company’s Form 8-K filed on January 10, 2011, SEC file number 000-30156-11520181.

3.3

Articles of Incorporation, as amended, of the Company incorporated by reference and included in the Company’s Form 8-K filed on January 10, 2014, SEC file number 000-30156-14521612.

3.4

By-laws of the Company incorporated by reference and included in the Company’s Registration Statement on Form 10-SB 12g filed on May 11, 1999, SEC file number 000-30156-99616992.

4.1

Convertible Promissory Note dated September 9, 2016, between Kalen Capital Corporation and the Company; incorporated by reference and included in the Company’s Form 8-K filed on September 16, 2016, SEC file number 000-30156-161888353

4.2

Series E Stock Purchase Warrant dated September 9, 2016; incorporated by reference and included in the Company’s Form 8-K filed on September 16, 2016, SEC file number 000-30156-161888353

4.3

Form of Convertible Promissory Note dated February 23, 2017; incorporated by reference and included in the Company’s Form 8-K filed on March 1, 2017, SEC file number 000-30156-17654590

4.4

Form of Series E Stock Purchase Warrant dated February 23, 2017; incorporated by reference and included in the Company’s Form 8-K filed on March 1, 2017, SEC file number 000-30156-17654590

10.1

Loan Agreement between Kalen Capital Corporation and RenovaCare, Inc. dated September 9, 2016 (Incorporated by reference to Form 8-K filed on September 16, 2016)

10.2

Form of Loan Agreement dated February 23, 2017; incorporated by reference and included in the Company’s Form 8-K filed on March 1, 2017, SEC file number 000-30156-17654590

31.1

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

32.1

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

 

101.INS

XBRL Instance Document**

101.SCH

XBRL Taxonomy Extension - Schema Document**

101.CAL

XBRL Taxonomy Extension - Calculation Linkbase Document**

101.DEF

XBRL Taxonomy Extension - Definition Linkbase Document**

 

101.LAB

XBRL Taxonomy Extension - Label Linkbase Document**

 

101.PRE

XBRL Taxonomy Extension - Presentation Linkbase Document**

____________

*

Filed herewith.

**

Furnished herewith. XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

 
26
 
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Sections 13 or 15 (d) of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

RenovaCare, Inc.

(Registrant)

Date: August 14, 2017

By:

/s/ Thomas Bold

Name:

Thomas Bold

Title:

Chief Executive Officer and Interim Chief Financial Officer

Principal Executive Officer and Principal Financial Officer)

 

 

27

 
EX-31.1 2 rcar_ex311.htm CERTIFICATION rcar_ex311.htm

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

I, Thomas Bold, certify that:

 

1.

I have reviewed this quarterly report on Form 10-Q of RenovaCare, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

 

5.

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Date: August 14, 2017

By:

/s/ Thomas Bold

Name:

Thomas Bold

Title:

Chief Executive Officer and Interim

Chief Financial Officer

(Principal Executive Officer and

Principal Financial Officer)

 

EX-32.1 3 rcar_ex321.htm CERTIFICATION rcar_ex321.htm

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350 of Chapter 63 of Title 18 of the United States Code), the undersigned officer of RenovaCare, Inc. (the "Company") do hereby certify with respect to the Quarterly Report of the Company on Form 10-Q for the period ended June 30, 2017 (the "Report") that:

 

 

(i)

the Report filed by the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

 

(ii)

The information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of the Company on the dates and for the periods presented therein.

 

RENOVACARE, INC.

Date: August 14, 2017

By:

/s/ Thomas Bold

 

Name:

Thomas Bold

Title:

Chief Executive Officer and Interim Chief Financial

Officer (Principal Executive Officer and Principal

Financial Officer)

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 4 rcar-20170630.xml XBRL INSTANCE DOCUMENT 0001016708 2017-08-08 0001016708 2017-06-30 0001016708 2016-12-31 0001016708 2017-01-01 2017-06-30 0001016708 2014-12-31 0001016708 rcar:DrGerlachMember 2016-12-31 0001016708 us-gaap:CommonStockMember 2015-12-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001016708 us-gaap:RetainedEarningsMember 2015-12-31 0001016708 2016-01-01 2016-06-30 0001016708 rcar:ExercisePriceRangeOneMember 2017-06-30 0001016708 rcar:ExercisePriceRangeTwoMember 2017-06-30 0001016708 rcar:ExercisePriceRangeThreeMember 2017-06-30 0001016708 rcar:ExercisePriceRangeFourMember 2017-06-30 0001016708 rcar:ExercisePriceRangeFiveMember 2017-06-30 0001016708 rcar:ExercisePriceRangeSixMember 2017-06-30 0001016708 rcar:ExercisePriceRangeSevenMember 2017-06-30 0001016708 rcar:ExercisePriceRangeEightMember 2017-06-30 0001016708 rcar:ExercisePriceRangeOneMember 2017-01-01 2017-06-30 0001016708 rcar:ExercisePriceRangeTwoMember 2017-01-01 2017-06-30 0001016708 rcar:ExercisePriceRangeThreeMember 2017-01-01 2017-06-30 0001016708 rcar:ExercisePriceRangeFourMember 2017-01-01 2017-06-30 0001016708 rcar:ExercisePriceRangeFiveMember 2017-01-01 2017-06-30 0001016708 rcar:ExercisePriceRangeSixMember 2017-01-01 2017-06-30 0001016708 rcar:ExercisePriceRangeSevenMember 2017-01-01 2017-06-30 0001016708 rcar:ExercisePriceRangeEightMember 2017-01-01 2017-06-30 0001016708 2016-06-30 0001016708 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001016708 us-gaap:CommonStockMember 2016-12-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001016708 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001016708 us-gaap:RetainedEarningsMember 2016-12-31 0001016708 us-gaap:MinimumMember 2016-01-01 2016-12-31 0001016708 us-gaap:MaximumMember 2016-01-01 2016-12-31 0001016708 us-gaap:SeriesAMember 2016-12-31 0001016708 us-gaap:SeriesBMember 2016-12-31 0001016708 rcar:SeriesCMember 2016-12-31 0001016708 rcar:SeriesDMember 2017-01-01 2017-06-30 0001016708 rcar:SeriesDMember 2016-12-31 0001016708 rcar:SeriesEMember 2016-12-31 0001016708 us-gaap:WarrantMember 2016-12-31 0001016708 rcar:SeriesDMember rcar:OnJuneFiveTwoThousandsFifteenMember 2015-12-31 0001016708 us-gaap:SeriesAMember rcar:DrGerlachMember 2016-12-31 0001016708 us-gaap:SeriesAMember rcar:DrGerlachMember 2014-07-12 0001016708 us-gaap:SeriesAMember rcar:DrGerlachMember 2015-07-12 0001016708 us-gaap:SeriesAMember rcar:DrGerlachMember 2016-07-12 0001016708 us-gaap:SeriesAMember rcar:DrGerlachMember 2017-07-12 0001016708 us-gaap:SeriesAMember rcar:DrGerlachMember 2018-07-12 0001016708 us-gaap:SeriesAMember rcar:DrGerlachMember 2015-08-05 0001016708 us-gaap:SeriesBMember 2013-11-29 0001016708 us-gaap:SeriesBMember 2016-02-02 0001016708 rcar:SeriesCMember 2013-11-29 0001016708 rcar:SeriesCMember 2016-09-09 0001016708 2014-06-01 2014-06-09 0001016708 rcar:KccMember rcar:SeriesBWarrantMember 2016-02-02 0001016708 rcar:KccMember rcar:SeriesBWarrantMember 2017-02-01 2017-03-01 0001016708 rcar:KccMember rcar:LoanAgreementMember rcar:SeriesEWarrantMember 2016-09-09 0001016708 rcar:KccMember rcar:LoanAgreementMember rcar:SeriesEWarrantMember 2016-09-01 2016-09-09 0001016708 rcar:KccMember rcar:LoanAgreementMember 2016-09-09 0001016708 rcar:KccMember rcar:LoanAgreementMember 2016-09-01 2016-09-09 0001016708 rcar:DrGerlachMember rcar:OptionAgreementMember 2015-04-30 2015-05-01 0001016708 rcar:DrGerlachMember rcar:OptionAgreementMember 2015-05-01 0001016708 rcar:DrGerlachMember 2017-04-01 2017-06-30 0001016708 rcar:DrGerlachMember 2016-04-01 2016-06-30 0001016708 rcar:CharitableGrantAgreementMember 2014-09-25 0001016708 rcar:CharitableGrantAgreementMember 2014-09-01 2014-09-25 0001016708 rcar:SatterleeStephensLlpMember 2016-12-31 0001016708 rcar:JosephSierchioMember 2016-12-31 0001016708 rcar:SeriesCMember 2016-09-01 2016-09-09 0001016708 rcar:ConsultingAgreementMember 2016-05-01 0001016708 rcar:ConsultingAgreementMember 2013-08-01 0001016708 rcar:PittsburghLifeSciencesGreenhouseMember 2015-02-28 2015-03-01 0001016708 rcar:PittsburghLifeSciencesGreenhouseMember 2017-02-26 2017-03-01 0001016708 rcar:StemCellSystemsMember 2017-04-01 2017-06-30 0001016708 rcar:StemCellSystemsMember 2016-04-01 2016-06-30 0001016708 rcar:TwoThousandThirteenPlanMember 2016-12-31 0001016708 rcar:TwoThousandThirteenPlanMember 2016-01-01 2016-12-31 0001016708 2015-12-31 0001016708 2016-01-01 2016-12-31 0001016708 us-gaap:StockCompensationPlanMember 2017-01-01 2017-06-30 0001016708 us-gaap:StockCompensationPlanMember 2016-01-01 2016-06-30 0001016708 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001016708 us-gaap:WarrantMember 2016-01-01 2016-06-30 0001016708 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-06-30 0001016708 us-gaap:ConvertibleDebtSecuritiesMember 2016-01-01 2016-06-30 0001016708 rcar:AssetPurchaseAgreementMember rcar:DrGerlachMember 2017-01-01 2017-03-31 0001016708 rcar:AssetPurchaseAgreementMember rcar:DrGerlachMember 2013-07-31 0001016708 us-gaap:SubsequentEventMember 2017-12-31 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember 2017-04-01 2017-06-30 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember us-gaap:InvestorMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember rcar:SeriesFWarrantMember 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember us-gaap:InvestorMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember rcar:SeriesFWarrantMember 2017-02-24 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:JosephSierchioMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember rcar:SeriesFWarrantMember 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:JosephSierchioMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember rcar:SeriesFWarrantMember 2017-02-24 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:KccMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember rcar:SeriesFWarrantMember 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:KccMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember rcar:SeriesFWarrantMember 2017-02-24 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember us-gaap:InvestorMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember us-gaap:InvestorMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember 2017-02-24 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:JosephSierchioMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:JosephSierchioMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember 2017-02-24 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:KccMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:KccMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember 2017-02-24 2017-03-09 0001016708 rcar:KccMember rcar:LoanAgreementMember 2017-04-01 2017-06-30 0001016708 us-gaap:SeriesAMember 2017-06-30 0001016708 us-gaap:SeriesBMember 2017-06-30 0001016708 rcar:SeriesCMember 2017-06-30 0001016708 rcar:SeriesDMember 2017-06-30 0001016708 rcar:SeriesEMember 2017-06-30 0001016708 rcar:SeriesFWarrantMember 2017-06-30 0001016708 us-gaap:WarrantMember 2017-06-30 0001016708 rcar:SeriesFWarrantMember 2016-12-31 0001016708 us-gaap:SeriesAMember 2017-01-01 2017-06-30 0001016708 us-gaap:SeriesBMember 2017-01-01 2017-06-30 0001016708 rcar:SeriesCMember 2017-01-01 2017-06-30 0001016708 rcar:SeriesEMember 2017-01-01 2017-06-30 0001016708 rcar:SeriesFWarrantMember 2017-01-01 2017-06-30 0001016708 rcar:SeriesFWarrantOneMember 2017-01-01 2017-06-30 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember rcar:SeriesFWarrantMember 2017-02-22 2017-03-09 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember rcar:SeriesFWarrantMember 2017-03-09 0001016708 rcar:SeriesDMember rcar:OnJuneFiveTwoThousandsFifteenMember 2016-12-06 0001016708 rcar:KccMember rcar:SeriesCWarrantMember 2017-02-26 2017-03-01 0001016708 rcar:KccMember rcar:SeriesBWarrantMember 2017-02-26 2017-03-01 0001016708 us-gaap:SeriesAMember rcar:DrGerlachMember 2017-01-01 2017-01-10 0001016708 us-gaap:SeriesAMember rcar:DrGerlachMember 2015-08-01 2015-08-05 0001016708 rcar:JosephSierchioMember 2017-06-30 0001016708 rcar:JosephSierchioMember 2017-01-01 2017-06-30 0001016708 rcar:KccMember rcar:SeriesBAndCWarrantsMember 2017-02-26 2017-03-01 0001016708 rcar:KccMember rcar:SeriesCWarrantMember 2017-03-01 0001016708 rcar:KccMember rcar:SeriesBWarrantMember 2017-03-01 0001016708 rcar:ThomasBoldMember us-gaap:StockOptionMember 2017-02-01 2017-02-17 0001016708 rcar:ThomasBoldMember us-gaap:StockOptionMember 2017-02-17 0001016708 rcar:JosephSierchioMember us-gaap:StockOptionMember 2017-02-01 2017-02-10 0001016708 rcar:JosephSierchioMember us-gaap:StockOptionMember 2017-02-10 0001016708 rcar:KennethKirklandMember us-gaap:StockOptionMember 2017-02-01 2017-02-02 0001016708 rcar:KennethKirklandMember us-gaap:StockOptionMember 2017-02-02 0001016708 rcar:DrGerlachMember rcar:SeriesAWarrantMember 2017-01-01 2017-01-10 0001016708 rcar:DrGerlachMember rcar:SeriesAWarrantMember 2017-01-10 0001016708 rcar:TwoThousandThirteenPlanMember 2017-06-30 0001016708 rcar:JosephSierchioMember 2016-03-15 0001016708 rcar:KennethKirklandMember 2016-03-15 0001016708 rcar:DrGerlachMember 2017-06-30 0001016708 rcar:KccMember rcar:LoanAgreementMember 2017-02-01 2017-02-23 0001016708 rcar:JosephSierchioMember rcar:LoanAgreementMember 2017-02-01 2017-02-23 0001016708 rcar:JosephSierchioMember rcar:LoanAgreementMember 2017-02-23 0001016708 rcar:KccMember rcar:LoanAgreementMember 2017-02-23 0001016708 rcar:JosephSierchioMember rcar:LoanAgreementMember rcar:SeriesFWarrantMember 2017-02-28 0001016708 rcar:KccMember rcar:LoanAgreementMember rcar:SeriesFWarrantMember 2017-02-28 0001016708 rcar:JosephSierchioMember rcar:LoanAgreementMember rcar:SeriesFWarrantMember 2017-02-01 2017-02-28 0001016708 rcar:KccMember rcar:LoanAgreementMember rcar:SeriesFWarrantMember 2017-02-01 2017-02-28 0001016708 2017-04-01 2017-06-30 0001016708 2016-04-01 2016-06-30 0001016708 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0001016708 us-gaap:CommonStockMember 2017-06-30 0001016708 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0001016708 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001016708 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0001016708 us-gaap:RetainedEarningsMember 2017-06-30 0001016708 us-gaap:PrivatePlacementMember 2017-06-01 2017-06-30 0001016708 us-gaap:StockCompensationPlanMember 2017-04-01 2017-06-30 0001016708 us-gaap:StockCompensationPlanMember 2016-04-01 2016-06-30 0001016708 us-gaap:WarrantMember 2017-04-01 2017-06-30 0001016708 us-gaap:WarrantMember 2016-04-01 2016-06-30 0001016708 us-gaap:ConvertibleDebtSecuritiesMember 2017-04-01 2017-06-30 0001016708 us-gaap:ConvertibleDebtSecuritiesMember 2016-04-01 2016-06-30 0001016708 rcar:FebruaryTwoThousandSeventeenLoanAgreementsMember rcar:FromFebruaryTwentyThreeToMarchNineTwoThousandSeventeenMember 2017-01-01 2017-06-30 0001016708 rcar:LoanAgreementMember 2017-01-01 2017-06-30 0001016708 rcar:SeriesFMember rcar:KccMember 2017-06-28 0001016708 rcar:SeriesFMember rcar:KccMember 2017-06-01 2017-06-28 0001016708 us-gaap:SeriesBMember 2016-02-01 2016-02-02 0001016708 us-gaap:MinimumMember 2017-01-01 2017-06-30 0001016708 us-gaap:MaximumMember 2017-01-01 2017-06-30 0001016708 rcar:ExercisePriceRangeNineMember 2017-06-30 0001016708 rcar:ExercisePriceRangeNineMember 2017-01-01 2017-06-30 0001016708 rcar:StemCellSystemsMember 2017-01-01 2017-06-30 0001016708 rcar:StemCellSystemsMember 2016-01-01 2016-06-30 0001016708 rcar:JosephSierchioMember 2017-06-30 0001016708 rcar:KennethKirklandMember 2017-06-30 0001016708 rcar:JosephSierchioMember 2017-01-01 2017-06-30 0001016708 rcar:JosephSierchioMember 2016-01-01 2016-06-30 0001016708 rcar:JosephSierchioMember 2017-04-01 2017-06-30 0001016708 rcar:JosephSierchioMember 2016-04-01 2016-06-30 0001016708 rcar:KennethKirklandMember 2017-01-01 2017-06-30 0001016708 rcar:JosephSierchioMember 2017-05-11 0001016708 rcar:KennethKirklandMember 2017-05-11 0001016708 rcar:JosephSierchioMember 2017-05-01 2017-05-11 0001016708 rcar:KennethKirklandMember 2017-05-01 2017-05-11 0001016708 2017-06-01 2018-05-11 0001016708 rcar:DrGerlachMember 2017-01-01 2017-06-30 0001016708 rcar:DrGerlachMember 2016-01-01 2016-06-30 0001016708 rcar:KccMember rcar:SeriesFWarrantMember 2017-06-28 0001016708 rcar:KccMember rcar:SeriesFWarrantMember 2017-06-01 2017-06-28 0001016708 rcar:KccMember rcar:SeriesCWarrantMember 2017-02-01 2017-03-01 0001016708 rcar:KccMember rcar:SeriesBWarrantMember 2016-02-01 2016-02-02 0001016708 rcar:BlackScholesMember 2017-01-01 2017-06-30 0001016708 rcar:BlackScholesMember 2017-06-30 0001016708 us-gaap:PrivatePlacementMember 2017-07-21 0001016708 rcar:SeriesGStockPurchaseWarrantMember 2017-06-30 0001016708 rcar:KccMember 2017-06-30 0001016708 rcar:SeriesGStockWarrantMember 2017-01-30 2017-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure rcar:Installment 75225418 0.0001 0.0001 10000000 10000000 0 0 0 0 0.00001 0.00001 2.92 2.44 2.68 500000000 500000000 Renovacare, Inc. 0001016708 10-Q 2017-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2017 74765168 70069693 74765168 70069693 0.0123 0.0141 0.0193 0.0293 0.923 0.92 0.98 1.06 -194091 239327 678 9197970 -8973695 702 11290209 -11051584 224953 749 12698944 -12893784 -1842200 -1308245 -1270376 -527354 -1842200 545000 10000 55000 7500 7500 10000 7500 130000 7500 310000 3.09 0.80 1.05 1.25 1.34 1.65 1.70 1.91 2.28 0.46 4.20 3.01 375000 10000 35000 7500 7500 10000 7500 130000 7500 160000 2.75 0.80 1.05 1.25 1.34 1.65 1.70 1.91 2.28 4.20 65506 33290 11750 11750 40000 211 53 223965 185632 24000 144885 73810 442941 418031 276147 397589 100000 1326087 2173913 3092637 1181194 114493 196812 13846 4273831 34296 38642 29642 204571 114493 2173913 114493 3092637 2173913 1010000 1200000 240000 3500000 3500000 584416 584416 20000000 7246 7246 114493 128985 20000 3500000 1326087 40000 70000 40000 240000 19338572 50000 50000 7246 114493 114493 75000 75000 (i) $1.54; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. (i) $1.54; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23. <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; background-color: White">(i) $1.54, the closing price of the Company&#146;s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company&#146;s common stock as quoted on the OTCQB for the five days prior to the date on which KCC elects to exercise the Warrant.</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i) $3.45, the closing price of the Company&#146;s common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i) $3.45, the closing price of the Company&#146;s common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i) $3.45, the closing price of the Company&#146;s common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i) $3.45, the closing price of the Company&#146;s common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i) $3.45, the closing price of the Company&#146;s common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i) $3.45, the closing price of the Company&#146;s common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">(i) $3.45, the closing price of the Company&#146;s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company&#146;s common stock as quoted on the OTCQB for the five days prior to the date on which the holder elects to exercise the Warrant</font></p> (i) $3.45; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76. (i) $3.45; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76. (i) $3.45; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. (i) $3.45; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. 900000 25000 25000 395000 0.07 0.07 0.07 0.07 0.07 0.07 750 800 6800 5000 52830 36000 106830 110567 1.91 1.91 4.20 4.20 180668 91515 77537 54665 8460 12060 18540 23940 24000 2017-12-31 2018-02-23 2018-02-23 2018-02-23 2018-02-23 2018-02-23 P5Y P5Y P5Y 0.80 1.05 1.25 1.34 1.65 1.70 1.91 2.28 4.20 Not be less than 110% of the fair market value 2023-06-20 397100 543319 534519 1.23 465987 449566 23046 31535 619581 603318 740 898 813672 363991 813672 363991 576681 165481 50542 15220 619581 603318 -12893784 -11051584 12698944 11290209 749 702 635010 16076 35866 7819 12698 20516 10824 25042 -418410 110517 133264 -243781 153347 265063 544 8924 67781934 70069693 74765168 2273913 4592895 344624 24 1109977 1110001 46 344578 13846 102580 1 -1 620872 296123 296123 620872 3407564 7233587 545000 437500 2228908 6796087 633656 3407564 7233587 545000 437500 2228908 6796087 633656 52852 100002 152854 152854 300000 50000 100000 50000 100000 100000 150000 700000 25000 395000 200000 1.54 0.0123 0.0181 0.00 0.00 P5Y P5Y 340735 488000 359265 700000 289939 289939 1.25 years <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The remaining debt discount of $400,456 will be amortized over the next three quarters through March 31, 2018</font></p> <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The remaining debt discount of $289,939 will be amortized over the next two quarters through December 31, 2017</font></p> 960000 1326087 3500000 910000 584416 7280503 720000 910000 584416 14492 2228908 1.10 0.35 0.46 0.46 0.49 0.35 0.46 0.49 1.10 1.54 3.45 3.01 2020-06-05 2019-07-12 2018-11-29 2018-11-29 2021-09-08 2022-02-23 2022-03-09 110001 1000000 110000 344624 P5Y P5Y 3 240000 240000 240000 240000 240000 443286 -2077889 -2077889 443286 545000 385000 257500 310000 180000 187500 -150000 -20000 19338572 3.09 1.42 1.07 4.20 1.92 1.65 1.12 0.80 P9Y1M13D P5Y6M P5Y6M P10Y 0.00 0.00 P9Y1M13D P7Y1M16D P6Y9M3D P7Y11M15D P8Y0M4D P8Y4M2D P8Y3M19D P8Y8M16D P9Y0M22D P9Y10M14D P8Y11M8D P7Y1M16D P6Y9M3D P7Y11M15D P8Y0M4D P8Y4M2D P8Y3M19D P8Y8M16D P9Y0M22D P9Y10M14D No person may be granted in any of the Company's fiscal year, options to purchase more than 2,000,000 shares under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant. The Company has the option to terminate the Lease on the twelve month anniversary of the commencement date, upon one hundred and twenty days' prior written notice. 6000 6000 18540 8460 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited financial statements of RenovaCare, Inc. (the &#147;Company&#148;) as of June 30, 2017, and for the three and six months ended June 30, 2017 and 2016, have been prepared in accordance with generally accepted accounting principles (&#147;GAAP&#148;) in the United States for interim financial reporting and include the Company&#146;s wholly-owned subsidiary, RenovaCare Sciences. Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, as filed with the Securities and Exchange Commission as part of the Company&#146;s Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Organization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RenovaCare, Inc., together with its wholly owned subsidiary, focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp., completed the acquisition of its flagship technologies (collectively, the &#147;<b>CellMist<sup>TM </sup>System</b>&#148;) along with associated United States patent applications and two foreign patent applications, the first of which was filed on August 23, 2007 (DE 10 2007 040 252.1) and the second of which was filed on April 27, 2011 (DE 10 2011 100 450.9), both of which have been granted. One of the US patent applications was granted on November 29, 2016 (Patent No. US 9,505,000) and the other patent application was granted on April 4, 2017 (Patent No. US 9,610,430).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CellMist<sup>TM</sup> System is comprised of (a) a treatment methodology for cell isolation for the regeneration of human skin cells (the &#147;<b>CellMist<sup>TM</sup> Solution</b>&#148;) and (b) a solution sprayer device (the &#147;<b>SkinGun<sup>TM</sup></b>&#148;) for delivering the cells to the treatment area. The Company has filed additional patent applications related to the CellMist<sup>TM</sup> Solution and SkinGun<sup>TM</sup> technologies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><b>Going Concern</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's activities have consisted principally of performing research and development activities and raising capital. These activities are subject to significant risks and uncertainties, including possible failure of preclinical testing and failing to secure additional funding before achieving sustainable revenue and profit from operations. The Company's ability to fund the development of its cellular therapies will depend on the amount and timing of cash receipts from future financing activities. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company&#146;s ability to establish itself as a profitable business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2017, the Company has a retained deficit of $12,893,784 and cash and cash equivalents of $442,941. In July 2017, the Company received Private Placement funding of $1.1 million. Based upon its current and near term anticipated level of operations and expenditures, the Company believes that cash on hand should be sufficient to enable it to continue operations through January 2018. If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company&#146;s business, operating results, financial condition and prospects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2016, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) No. 2016-09, &#147;Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)&#148;, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02, &#147;Leases (Topic 842)&#148;, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC Topic 842, Leases. ASU 2016-02 requires lessees to recognize a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months on its balance sheet. ASU 2016-02 also expands the required quantitative and qualitative disclosures surrounding leases. ASU 2016-02 is effective for the Company beginning January 1, 2019. Early adoption is permitted. The Company has determined that the adoption of ASU 2016-02 will currently have no impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2015, the FASB issued ASU No. 2015-17, &#147;Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes&#148; (&#147;ASU 2015-17&#148;). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09, &#147;Revenue from Contracts with Customers (Topic 606)&#148;, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017, and early adoption is permitted. The Company has determined that the adoption of ASU 2014-09 will currently have no impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company&#146;s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Earnings (Loss) Per Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company presents both basic and diluted earnings per share (&#147;EPS&#148;) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is the computation of basic and diluted net loss per share for the three and six months ended June 30, 2017 and 2016:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" id="hdcell" style="text-align: center"><font style="font-size: 10pt"><b>Three Months Ended</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>Six Months Ended</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt"><b>Basic and Diluted EPS Computation</b></font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Numerator: </font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Loss available to common stockholders' </font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(1,270,376</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(527,354</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(1,842,200</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(1,308,245</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Denominator: </font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Weighted average number of common shares outstanding</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">74,653,184</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">69,955,847</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">73,174,724</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">69,561,676</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Basic and diluted EPS</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.02</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.03</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.02</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares listed below were not included in the computation of diluted losses</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">per share because to do so would have been antidilutive for the periods presented:</p></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Stock options</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">545,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">437,500</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">545,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">437,500</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Warrants</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">2,228,908</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">6,796,087</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">2,228,908</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">6,796,087</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Convertible debt</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">633,656</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">633,656</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Total shares not included in the computation of diluted losses per share</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">3,407,564</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">7,233,587</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">3,407,564</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">7,233,587</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement (&#147;APA&#148;) with Dr. J&#246;rg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach&#146;s rights, title and interest in the CellMist<sup>TM</sup> System. Acquisition related costs amounted to $52,852 and were capitalized together with the cash payment upon the closing of the transaction in July 2013 of $100,002. Intangible assets amounted to $152,854 at June 30, 2017 and December 31, 2016.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 9, 2014, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an amended asset purchase agreement (the &#147;Amended APA&#148;) with Dr. J&#246;rg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach's rights, title and interest in the CellMist&#153; System. The Amended APA provided for cash payments of $300,000 as partial consideration for the purchase which are payable as follows: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. At June 30, 2017, $100,000 of the amount payable to Dr. Gerlach was recorded as current liabilities in the accompanying consolidated balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><b>September 9, 2016, $700,000 Convertible Promissory Note</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">On September 9, 2016, the Company entered into a loan agreement (the &#147;Loan Agreement&#148;) with Kalen Capital Corporation (&#147;KCC&#148;); KCC is wholly owned by Mr. Harmel S. Rayat, the Company's majority shareholder. Pursuant to the terms of the Loan Agreement, KCC agreed to loan the Company up to $900,000 at an annual interest rate of 7% per year, compounded quarterly. KCC provided the Company with an initial loan in the amount of $700,000, which was evidenced by a convertible promissory note (the &#147;Note&#148;); the remaining $200,000 may be loaned prior to December 31, 2017, upon the mutual agreement of the Company and KCC. The Note, including any interest due thereon, may be prepaid at any time without penalty. The Note matures on December 31, 2017, and, beginning on the first anniversary of the Note, can be converted, at KCC&#146;s sole discretion, into shares of the Company&#146;s common stock at conversion rate equal to the lesser of: (i) $1.54, or the closing price of the Company&#146;s common stock on the day prior to the issuance of the Note or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">Per the Loan Agreement, the Company issued KCC a Series E Stock Purchase Warrant (the &#147;Series E Warrant&#148;) to purchase up to 584,416 shares of the Company&#146;s common stock at a purchase price of the lesser of: (i) $1.54, the closing price of the Company&#146;s common stock on the day prior to issuance of the Series E Warrant; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. The Series E Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Loan Agreement provides KCC with registration rights for all of the shares issuable upon conversion of the Note, including conversion of the note issued for the remaining $200,000, if applicable, and exercise of the Series E Warrant, beginning on the first anniversary of the Loan Agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company calculated the debt discount related to the Note and Series E Warrant by first allocating the respective fair value of the Note and Series E Warrant based upon their relative fair values to the total Note proceeds. The fair value of the Series E Warrant issued with the Note was calculated using the Black-Scholes option pricing model and the following assumptions: exercise price - $1.25 per share; market price of common stock - $1.54 per share; estimated volatility &#150; 92.3%; risk free interest rate - 1.23%; expected dividend rate - 0% and expected life - 5.0 years. The resulting fair value of $340,735 was allocated to the Series E Warrant. The intrinsic value of the beneficial conversion feature amounted to $359,265. The resulting $700,000 discount to the Note is being accreted over the 1.25 year term of the Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and six months ended June 30, 2017, the Company recognized $12,698 and $25,042 of interest expense and $133,264 and $265,063 of accretion related to the debt discount. The remaining debt discount of $269,456 will be amortized over the next two quarters through December 31, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>February 2017, $445,000 Convertible Promissory Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">Between February 23, 2017 and March 9, 2017, the Company entered into three separate loan agreements containing identical terms (the &#147;February 2017 Loan Agreements&#148;) with Joseph Sierchio (&#147;Sierchio&#148;), an investor (the &#147;Investor&#148;) and KCC (collectively, the &#147;Holders&#148;). Pursuant to the terms of the February 2017 Loan Agreements, Sierchio and the Investor each agreed to loan the Company $25,000 and KCC agreed to loan the Company $395,000 at an annual interest rate of 7% per year, compounded quarterly. Each loan was evidenced by a convertible promissory note (collectively, the &#147;February 2017 Notes&#148;). The February 2017 Notes, including any interest due thereon, may not be prepaid without the consent of the Holders. The February 2017 Notes mature on February 23, 2018, and, beginning on the one month anniversary, can be converted, at the Holders&#146; sole discretion, into shares of the Company&#146;s common stock at conversion rate equal to the lesser of: (i) $3.45, the closing price of the Company&#146;s common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">Per the February 2017 Loan Agreement, the Company issued Sierchio, the Investor and KCC a Series F Stock Purchase Warrant (the &#147;Series F Warrant&#148;) to purchase up to 7,246 shares, 7,246 shares and 114,493 shares, respectively, of the Company&#146;s common stock at an exercise price per share equal to the lesser of: (i) $3.45, the closing price of the Company&#146;s common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. The Series F Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The February 2017 Loan Agreements provide the Holders with registration rights for all of the shares issuable upon conversion of the February 2017 Notes, including exercise of the Series F Warrants, beginning on the first anniversary of the February 2017 Loan Agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and six months ended June 30, 2017, the Company recognized $7,819 and $10,824 of interest expense and $110,517 and $153,347 of accretion related to the debt discount. The remaining debt discount of $289,939 will be amortized over the next three quarters through March 31, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective March 1, 2015, the Company entered into a lease agreement (the &#147;Lease&#148;) in the Pittsburgh Life Sciences Greenhouse at a monthly rate of $750. The Company has the option to terminate the Lease on the twelve month anniversary of the commencement date, upon one hundred and twenty days&#146; prior written notice. The Lease was renewed effective March 1, 2017 at a monthly rate of $800.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2013, the Company and Vector Asset Management, Inc. (&#147;Vector&#148;) entered into a Consulting Agreement whereby Vector will assist the Company with identifying subject matter experts in the medical device and biotechnology industries and to assist the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology (collectively, the &#147;Services&#148;). On May 1, 2016, Vector and the Company entered into an amendment to the consulting agreement. Pursuant to the amendment, the term of the agreement terminates only upon written notice, and the monthly consulting fee, in consideration of the Services, was increased to $6,800 from $5,000. No other changes were made to the agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&#146;s anticipated regulatory filings, the Company has engaged StemCell Systems GmbH (&#147;StemCell Systems&#148;) to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $52,830 and $36,000 during the three months ended June 30, 2017 and 2016, respectively, and $106,830 and $110,567 during the six months ended June 30, 2017 and 2016, respectively. Dr. Gerlach, from whom the Company purchased the CellMist<sup>TM</sup> System technologies, is a principal of StemCell Systems.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See also &#147;Note 8. Related Party Transactions.&#148;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio will receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service. Additionally, on March 15, 2016, the Company granted to each of Dr. Kirkland and Mr. Sierchio an incentive stock option to purchase up to 50,000 shares of the Company&#146;s common stock at an exercise price of $1.91 per share. The options became fully vested upon grant. On May 11, 2017, the Company granted to each of Dr. Kirkland and Mr. Sierchio an incentive stock option to purchase up to 75,000 shares of the Company&#146;s common stock at an exercise price of $4.20 per share. 37,500 of the May 11 grant vested immediately with the remaining 37,500 vesting in one year on May 11, 2018. The option strike prices equal the closing price of the Company&#146;s common stock on the day of grant. The Options may be exercised on a &#147;cashless basis&#148; using the formula contained therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The law firm of Sierchio &#38; Partners, LLP, of which Joseph Sierchio, one of the Company&#146;s directors, was a principal, has provided counsel to the Company since August 26, 2010 and beginning in September 2016, Mr. Sierchio became a partner at Satterlee Stephens LLP (&#147;Satterlee&#148;). Concurrently with Mr. Sierchio&#146;s move to Satterlee, the Company engaged wih Satterlee to provide legal counsel with Mr. Sierchio maintaining his role as the Company&#146;s primary attorney. During the three months ended June 30, 2017 and 2016, the Company recognized $77,537 and $54,665 of fees for legal services billed by firms associated with Mr. Sierchio. During the six months ended June 30, 2017 and 2016, the Company recognized $180,668 and $91,515 of fees for legal services billed by firms associated with Mr. Sierchio. Included in accounts payable, at June 30, 2017 and December 31, 2016, is $40,000 and $11,750, respectively, owed to Satterlee. Mr. Sierchio continues his role with the Company as a director.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Company&#146;s anticipated regulatory filings, the Company has engaged StemCell Systems to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $52,830 and $36,000 during the three months ended June 30, 2017 and 2016, respectively, and $106,830 and $110,567 during the six months ended June 30, 2017 and 2016, respectively. Dr. Gerlach, from whom the Company purchased the CellMist<sup>TM</sup> System technologies, is a principal of StemCell Systems.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University, pursuant to which the Company committed to provide a charitable donation to the University in the aggregate amount of $75,000. The Company paid the Grant in eight quarterly installments of $9,375, with the final payment made on July 22, 2016. Dr. Gerlach, from whom the Company purchased the CellMist<sup>TM</sup> System technologies, is a professor at the University.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Gerlach is entitled to payments for consulting services. During the three months ended June 30, 2017 and 2016, the Company recognized expenses related to Dr. Gerlach services of $8,460 and $12,060, respectively. During the Six months ended June 30, 2017 and 2016, the Company recognized expenses related to Dr. Gerlach services of $18,540 and $23,940, respectively. Accounts payable to Dr. Gerlach amounted to $8,460 and $18,540 at June 30, 2017 and December 31, 2016, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2015, the Company entered into the Option Agreement with Dr. Gerlach, pursuant to which the Company obtained a one-year exclusive option to evaluate the Technology, for the purpose of determining whether the Company would like to purchase or license the Technology. Pursuant to the terms of the Option Agreement, the Company paid Dr. Gerlach a non-refundable fee of $24,000, payable in four quarterly installments of $6,000, with the first installment due on May 1, 2015. The entire $24,000 option payment was recognized as research and development expense during the period ended December 31, 2015. The final $6,000 payment was made on February 1, 2016.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">On September 9, 2016, the Company entered into the Loan Agreement with KCC whereby KCC agreed to loan the Company up to $900,000 at an interest rate of 7%. KCC provided the Company with an initial loan of $700,000; the remaining $200,000 may be loaned prior to December 31, 2017. The Note matures on December 31, 2017, and, beginning on the first anniversary of the Note, can be converted into shares of the Company&#146;s common stock at conversion rate equal to the lesser of: (i) $1.54; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">Per the Loan Agreement, the Company issued KCC a Series E Warrant to purchase up to 584,416 shares of the Company&#146;s common stock at a purchase price of the lesser of: (i) $1.54; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. The Series E Warrant is exercisable for a period of five years and may be exercised on a cashless basis, See &#147;Note 4. Debt&#148; for additional disclosure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">On February 23, 2017, the Company entered into two of the February 2017 Loan Agreements with Sierchio and KCC pursuant to which Sierchio loaned the Company $25,000 and KCC loaned $395,000 at an interest rate of 7%. The February 2017 Notes mature on February 23, 2018, and, beginning on the one month anniversary, can be converted into shares of the Company&#146;s common stock at conversion rate equal to the lesser of: (i) $3.45; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Per the February 2017 Loan Agreement, the Company issued Sierchio, and KCC a Series F Warrant to purchase up to 7,246 shares and 114,493 shares, respectively, of the Company&#146;s common stock at an exercise per share equal to the lesser of: (i) $3.45; or (ii) a 20% discount to the average closing price of the Company&#146;s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. The Series F Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis. See &#147;Note 4. Debt&#148; for additional disclosure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">March 1, 2017, KCC exercised 1,326,087 Series B Warrants and 3,092,637 Series C Warrants, on a cashless basis, resulting in the issuance of 4,273,831 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 17, 2017, Thomas Bold, the Company&#146;s President, CEO and Interim Chief Financial Officer exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 34,296 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 10, 2017, Joseph Sierchio, a member of the Company&#146;s board of directors, exercised options to purchase up to 70,000 shares, on a cashless basis, resulting in the issuance of 38,642 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Company&#146;s common stock at an exercise price of $0.46 per share resulting in proceeds of $1,000,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 2, 2017, Kenneth Kirkland, a member of the Company&#146;s board of directors, exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 29,642 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares, on a cashless basis, resulting in the issuance of 204,571 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">On July 21, 2017, the Company completed a self-directed offering of 460,250 units of the Company's equity securities (the &#34;Units&#34;) at a price of $2.44 per unit for $1,123,010 in aggregate proceeds (the &#147;July 2017 Private Placement&#148;). Each unit consists of (a) one share of common stock and one Series G Stock Purchase Warrant (the &#147;Series G Warrants&#148;) allowing the holder to purchase one (1) share of the Company&#146;s common stock at a price of $2.68 per share for a period of five years. The warrants may be exercised on a cashless basis. Of the 460,250 Units purchased, KCC purchased 410,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">The relative fair value of the common stock was estimated to be $635,010. The relative fair value of the Series G Warrants was estimated to be $488,000 as determined based on the relative fair value allocation of the proceeds received. The Series G Warrants were valued using the Black-Scholes option pricing model using the following variables: market price of common stock - $2.92 per share; estimated volatility &#150; 102.23%; 5-year risk free interest rate &#150; 1.81%; expected dividend rate - 0% and expected life - 5 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">The Company intends to use the proceeds from the July 2017 Private Placement for general corporate purposes, including the continued research and development of the Company&#146;s SkinGunTM and CellMistTM technologies and for working capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify">The July 2017 Private Placement was conducted pursuant to exemptions from the registration requirements afforded by, among others, Rule 506(c) of Regulation D (&#34;Regulation D&#34;) and Regulation S (&#34;Regulation S&#34;), as promulgated under the Securities Act of 1933, as amended. Accordingly, the Offering was available only to investors who reasonably verify to the Company that they are &#34;accredited investors,&#34; as such term is defined in Rule 501(a) of Regulation D or who are not U.S. Persons, as such term is defined in Rule 902 of Regulation S.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited financial statements of RenovaCare, Inc. (the &#147;Company&#148;) as of June 30, 2017, and for the three and six months ended June 30, 2017 and 2016, have been prepared in accordance with generally accepted accounting principles (&#147;GAAP&#148;) in the United States for interim financial reporting and include the Company&#146;s wholly-owned subsidiary, RenovaCare Sciences. Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, as filed with the Securities and Exchange Commission as part of the Company&#146;s Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is the computation of basic and diluted net loss per share for the three and six months ended June 30, 2017 and 2016:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" id="hdcell" style="text-align: center"><font style="font-size: 10pt"><b>Three Months Ended</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>Six Months Ended</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt"><b>Basic and Diluted EPS Computation</b></font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Numerator: </font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Loss available to common stockholders' </font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(1,270,376</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(527,354</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(1,842,200</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(1,308,245</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Denominator: </font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Weighted average number of common shares outstanding</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">74,653,184</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">69,955,847</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">73,174,724</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">69,561,676</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Basic and diluted EPS</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.02</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.03</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.02</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares listed below were not included in the computation of diluted losses</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">per share because to do so would have been antidilutive for the periods presented:</p></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Stock options</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">545,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">437,500</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">545,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">437,500</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Warrants</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">2,228,908</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">6,796,087</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">2,228,908</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">6,796,087</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Convertible debt</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">633,656</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">633,656</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Total shares not included in the computation of diluted losses per share</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">3,407,564</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">7,233,587</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">3,407,564</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">7,233,587</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about warrants outstanding at June 30, 2017 and December 31, 2016:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td colspan="2">&#160;</td> <td colspan="3" style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>Shares of Common Stock Issuable from Warrants Outstanding as of</b></font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td rowspan="2" style="width: 15%; border-bottom-style: solid; border-bottom-width: 1pt; font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>Description</b></font></td> <td rowspan="2" style="width: 4%">&#160;</td> <td style="width: 16%; font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td style="width: 3%; font: 12pt Times New Roman, Times, Serif; text-align: center">&#160;</td> <td style="width: 17%; font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td> <td rowspan="2" style="width: 3%">&#160;</td> <td rowspan="2" style="width: 16%; border-bottom-style: solid; border-bottom-width: 1pt"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td> <td rowspan="2" style="width: 3%">&#160;</td> <td rowspan="2" style="width: 23%; border-bottom-style: solid; border-bottom-width: 1pt; font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>Expiration</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Series A</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">720,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">960,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">$ 0.35 </font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">July 12, 2019</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Series B</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">1,326,087</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">$ 0.46</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">November 29, 2018</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Series C</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">3,500,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">$ 0.49</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">November 29, 2018</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Series D</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">910,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">910,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">$ 1.10</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">June 5, 2020</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Series E</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">584,416</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">584,416</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">$ 1.54</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">September 8, 2021</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Series F</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">14,492</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">$ 3.45</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">February 23, 2022 &#38; March 9, 2022</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Total</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right"><font style="font-size: 10pt">2,228,908</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right"><font style="font-size: 10pt">7,280,503</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes stock option activity for the six months ended June 30, 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="width: 46%">&#160;</td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="width: 12%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p></td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="width: 11%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price ($)</b></p></td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="width: 12%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Term </b></p></td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="width: 11%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Value ($)</b></p></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Outstanding at December 31, 2015</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">257,500</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.07</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Grants</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">187,500</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.92</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Forfeitures</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(40,000)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.65</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Exercises</font></td> <td style="text-align: justify">&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">(20,000)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.80</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Outstanding at December 31, 2016</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">385,000</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.42</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Grants</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">310,000</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4.20</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Exercises</font></td> <td style="text-align: justify">&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">(150,000)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.12</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Outstanding at June 30, 2017</font></td> <td style="text-align: justify">&#160;</td> <td style="border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right"><font style="font-size: 10pt">545,000</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3.09</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">9.12 years</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">501,425</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Exercisable at June 30, 2017</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">375,000</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.75</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">8.94 years</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">447,425</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Available for grant at June 30, 2017</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">19,338,572</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Risk-free interest rate</font></td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="text-align: right"><font style="font-size: 10pt">1.93% - 2.39 </font></td> <td style="text-align: justify"><font style="font-size: 10pt">%</font></td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="text-align: right"><font style="font-size: 10pt">1.23%- 1.41</font></td> <td style="text-align: justify"><font style="font-size: 10pt">%</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Expected life in years</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="text-align: right"><font style="font-size: 10pt">5.5&#160;- 10.0</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td id="ffcell" style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">5.5</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Weighted Avg. Expected Volatility</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="text-align: right"><font style="font-size: 10pt">98% - 106</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">%</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">92</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">%</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Expected dividend yield</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 11%; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 11%; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td></tr> </table> 40000 3.38 1.40 37500 1.25 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2017, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share, 74,765,168 shares of common stock outstanding and 19,338,572 shares reserved for issuance under the Company&#146;s 2013 Long-Term Incentive Plan (the &#147;2013 Plan&#148;) as adopted and approved by the Company&#146;s Board of Directors (the &#147;Board&#148;) on June 20, 2013 that provides for the grant of stock options to employees, directors, officers and consultants (See &#147;Note 6. Stock Options&#148;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2017, the Company had the following common stock related transactions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr> <td style="width: 4%; text-align: justify">&#160;</td> <td style="vertical-align: top; width: 4%; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624.</font></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">March 1, 2017, KCC exercised 1,326,087 Series B Warrants and 3,500,000 Series C Warrants, on a cashless basis, resulting in the issuance of 4,273,831 shares of common stock.</font></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">On February 17, 2017, Thomas Bold, the Company&#146;s President, CEO and Interim Chief Financial Officer exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 34,296 shares of common stock.</font></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">On February 10, 2017, Joseph Sierchio, a member of the Company&#146;s board of directors, exercised options to purchase up to 70,000 shares, on a cashless basis, resulting in the issuance of 38,642 shares of common stock.</font></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">On February 2, 2017, Kenneth Kirkland, a member of the Company&#146;s board of directors, exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 29,642 shares of common stock.</font></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares, on a cashless basis, resulting in the issuance of 204,571 shares of common stock.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2016, the Company had the following common stock related transactions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr> <td style="width: 4%; text-align: justify">&#160;</td> <td style="vertical-align: top; width: 4%; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">issued 100,000 shares of common stock, upon the exercise of a Series D Warrant at an exercise price of $1.10 per share resulting in $110,001 of proceeds to the Company.</font></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">issued 2,173,913 shares of common stock to KCC on February 2, 2016, upon the exercise of a portion of its Series B Warrant at an exercise price of $0.46 per share resulting in $1,000,000 of proceeds to the Company.</font></td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="text-align: justify">&#160;</td> <td style="vertical-align: top; text-align: justify"><font style="font: 10pt Symbol">&#183;</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">issued 13,846 shares of common stock upon the cashless exercise of an option to purchase 20,000 shares by Joseph Sierchio, a director.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about warrants outstanding at June 30, 2017 and December 31, 2016:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td colspan="2">&#160;</td> <td colspan="3" style="text-align: center"><font style="font-size: 10pt"><b>Shares of Common Stock Issuable from Warrants Outstanding as of</b></font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt"><b>Weighted</b></font></td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td rowspan="2" style="width: 15%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>Description</b></font></td> <td rowspan="2" style="width: 4%">&#160;</td> <td style="width: 16%; text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td style="width: 3%; text-align: center">&#160;</td> <td style="width: 17%; text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td> <td rowspan="2" style="width: 3%">&#160;</td> <td rowspan="2" style="width: 16%; border-bottom-style: solid; border-bottom-width: 1pt"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td> <td rowspan="2" style="width: 3%">&#160;</td> <td rowspan="2" style="width: 23%; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>Expiration</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td>&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Series A</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">720,000</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">960,000</font></td> <td>&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">$ 0.35 </font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">July 12, 2019</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Series B</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,326,087</font></td> <td>&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">$ 0.46</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">November 29, 2018</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Series C</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3,500,000</font></td> <td>&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">$ 0.49</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">November 29, 2018</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Series D</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">910,000</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">910,000</font></td> <td>&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">$ 1.10</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">June 5, 2020</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Series E</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">584,416</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">584,416</font></td> <td>&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">$ 1.54</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">September 8, 2021</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Series F</font></td> <td>&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">14,492</font></td> <td>&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">$ 3.45</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">February 23, 2022 &#38; March 9, 2022</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Total</font></td> <td>&#160;</td> <td style="border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right"><font style="font-size: 10pt">2,228,908</font></td> <td>&#160;</td> <td style="border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right"><font style="font-size: 10pt">7,280,503</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As consideration for the CellMist<sup>TM</sup> System and services performed in connection therewith, the Company issued to Dr. Gerlach a Series A Stock Purchase Warrant entitling him to purchase 1,200,000 shares of the Company&#146;s common stock at an exercise price of $0.35 per share. Pursuant to the terms of the Amended APA, the Series A Warrant will vest in five equal installments of 240,000 shares on each of July 12, 2014, July 12, 2015, July 12, 2016, July 12, 2017 and July 12, 2018. On August 5, 2015, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares on a cashless basis and the Company issued him 196,812 shares of common stock. On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares on a cashless basis and the Company issued him 204,571 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Series B Warrant with an exercise price of $0.46 to purchase 3,500,000 shares of common stock was issued on November 29, 2013 to KCC in connection with the 11/29 Financing. On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Company&#146;s common stock resulting in proceeds of $1,000,000. On March 1, 2017, KCC exercised, in full, on a cashless basis, the remaining 1,326,087 Series B Warrants resulting in the issuance of 1,181,194 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Series C Warrant with an exercise price of $0.49, to purchase 3,500,000 shares of common stock was issued on November 29, 2013 to KCC in connection with a financing. On March 1, 2017, KCC exercised, in full, on a cashless basis, the 3,500,000 Series C Warrants resulting in the issuance of 3,092,637 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Series D Warrants with an exercise price of $1.10 to purchase 1,010,000 shares of common stock were issued on June 5, 2015 in connection with the sale of units pursuant to a private placement. On December 6, 2016, a Series D Warrant to purchase shares was exercised resulting in the Company receiving $110,000 of proceeds.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Series E Warrant to purchase 584,416 shares of common stock was issued on September 9, 2016 in connection with the Loan Agreement. The Series E Warrant has an exercise price of the lesser of: (i) $1.54, the closing price of the Company&#146;s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company&#146;s common stock as quoted on the OTCQB for the five days prior to the date on which KCC elects to exercise the Warrant. The Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Three Series F Warrants to purchase 128,985 shares of common stock were issued between February 22, 2017 and March 9, 2017 in connection with the February 2017 Loan Agreements. The Series F Warrants have an exercise price of the lesser of: (i) $3.45, the closing price of the Company&#146;s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company&#146;s common stock as quoted on the OTCQB for the five days prior to the date on which the holder elects to exercise the Warrant. The Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein. On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 20, 2013, the Company&#146;s Board adopted the 2013 Long-Term Incentive Plan and on November 15, 2013, a stockholder owning a majority of the Company&#146;s issued and outstanding stock approved adoption to the 2013 Plan. Pursuant to the terms of the 2013 Plan, an aggregate of 20,000,000 shares of the Company&#146;s common stock are reserved for issuance to the Company&#146;s officers, directors, employees and consultants in order to attract and hire key technical personnel and management. Options granted to employees under the 2013 Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the 2013 Plan are limited to non-qualified stock options. As of June 30, 2017, there were 19,338,572 shares available for grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2013 Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Company's fiscal year, options to purchase more than 2,000,000 shares under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The exercise price per share of common stock for options granted under the 2013 Plan will be the fair market value of the Company's common stock on the date of grant, using the closing price of the Company's common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company's common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the 2013 Plan after June 20, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock Option Activity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes stock option activity for the six months ended June 30, 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="width: 46%">&#160;</td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="width: 12%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p></td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="width: 11%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price ($)</b></p></td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="width: 12%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Contractual Term </b></p></td> <td style="width: 2%; text-align: justify">&#160;</td> <td style="width: 11%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Intrinsic</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Value ($)</b></p></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Outstanding at December 31, 2015</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">257,500</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.07</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Grants</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">187,500</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.92</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Forfeitures</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(40,000)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.65</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Exercises</font></td> <td style="text-align: justify">&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">(20,000)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.80</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Outstanding at December 31, 2016</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">385,000</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.42</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Grants</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">310,000</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">4.20</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Exercises</font></td> <td style="text-align: justify">&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">(150,000)</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.12</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Outstanding at June 30, 2017</font></td> <td style="text-align: justify">&#160;</td> <td style="border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right"><font style="font-size: 10pt">545,000</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">3.09</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">9.12 years</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">501,425</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Exercisable at June 30, 2017</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">375,000</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.75</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">8.94 years</font></td> <td style="text-align: right">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">447,425</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Available for grant at June 30, 2017</font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">19,338,572</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. There were 310,000 stock options granted during the six months ended June 30, 2017 with a weighted-average grant date fair value of $3.38. There were 180,000 stock options granted during the six months ended June 30, 2016 with a weighted-average grant date fair value of $1.40. There were 150,000 options exercised on a cashless basis resulting in the issuance of 102,582 shares of common stock during the six months ended June 30, 2017, with an aggregate intrinsic value of $397,100. There were no stock options exercised during the six months ended June 30, 2016. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company's historical experience. The risk-free interest rate is based on a U.S. treasury note with maturity similar to the option award's expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Risk-free interest rate</font></td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="text-align: right"><font style="font-size: 10pt">1.93% - 2.39 </font></td> <td style="text-align: justify"><font style="font-size: 10pt">%</font></td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="text-align: right"><font style="font-size: 10pt">1.23%- 1.41</font></td> <td style="text-align: justify"><font style="font-size: 10pt">%</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Expected life in years</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="text-align: right"><font style="font-size: 10pt">5.5&#160;- 10.0</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td id="ffcell" style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">5.5</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Weighted Avg. Expected Volatility</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="text-align: right"><font style="font-size: 10pt">98% - 106</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">%</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">92</font></td> <td style="vertical-align: bottom; text-align: justify"><font style="font-size: 10pt">%</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; width: 509px; text-align: justify"><font style="font-size: 10pt">Expected dividend yield</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time is expensed ratably over the respective vesting periods. During the three months ended June 30, 2017 and 2016, the Company recognized $617,878 and $1,169, respectively, in share-based compensation. During the six months ended June 30, 2017 and 2016, the Company recognized $620,872 and $274,287, respectively, in share-based compensation. Stock-based compensation has been included in the Consolidated Statement of Operations as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended June 30,</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Six Months Ended June 30,</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Research and development</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">64,790</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">64,790</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">General and administrative</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">553,088</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1,171</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">556,082</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">274,287</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Total</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">617,878</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1,171</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">620,872</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">274,287</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about stock options outstanding and exercisable at June 30, 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="5" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>Stock Options Outstanding</b></font></td> <td>&#160;</td> <td colspan="5" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>Stock Options Exercisable</b></font></td></tr> <tr style="vertical-align: bottom"> <td rowspan="4" style="width: 9%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Range of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Prices</b></p></td> <td style="width: 2%">&#160;</td> <td rowspan="4" style="width: 18%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of Shares Subject to Outstanding Options</b></font></td> <td style="width: 2%">&#160;</td> <td rowspan="4" style="width: 13%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Contractual Life (years)</b></font></td> <td style="width: 2%">&#160;</td> <td rowspan="4" style="width: 11%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Exercise Price</b></font></td> <td style="width: 2%">&#160;</td> <td rowspan="4" style="width: 11%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of Shares Subject To Options Exercise</b></font></td> <td style="width: 2%">&#160;</td> <td rowspan="4" style="width: 13%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average Remaining Contractual</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Life (Years)</b></p></td> <td style="width: 2%; text-align: center">&#160;</td> <td rowspan="4" style="width: 13%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><font style="font-size: 10pt">0.80</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">10,000</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">7.13</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">0.80</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">10,000</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">7.13</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">0.80</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">1.05</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">55,000</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">6.76</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.05</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">35,000</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">6.76</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.05</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><font style="font-size: 10pt">1.25</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">7.96</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.25</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">7.96</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.25</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">1.34</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">8.01</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.34</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">8.01</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.34</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><font style="font-size: 10pt">1.65</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">10,000</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">8.34</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.65</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">10,000</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">8.34</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.65</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">1.70</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">8.30</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.70</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">8.30</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.70</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><font style="font-size: 10pt">1.91</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">130,000</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">8.71</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.91</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">130,000</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">8.71</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">1.91</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">2.28</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">9.06</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">2.28</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">9.06</font></td> <td>&#160;</td> <td style="text-align: center"><font style="font-size: 10pt">2.28</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center"><font style="font-size: 10pt">4.20</font></td> <td>&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">310,000</font></td> <td>&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt">9.87</font></td> <td>&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt">4.20</font></td> <td>&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">160,000</font></td> <td>&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt">9.87</font></td> <td>&#160;</td> <td style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt">4.20</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: center"><font style="font-size: 10pt">Total</font></td> <td>&#160;</td> <td style="border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right"><font style="font-size: 10pt">545,000</font></td> <td>&#160;</td> <td style="border-bottom-style: double; border-bottom-width: 2.25pt; text-align: center"><font style="font-size: 10pt">9.12</font></td> <td>&#160;</td> <td style="border-bottom-style: double; border-bottom-width: 2.25pt; text-align: center"><font style="font-size: 10pt">$3.09</font></td> <td>&#160;</td> <td style="border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right"><font style="font-size: 10pt">375,000</font></td> <td>&#160;</td> <td style="border-bottom-style: double; border-bottom-width: 2.25pt; text-align: center"><font style="font-size: 10pt">8.94</font></td> <td>&#160;</td> <td style="border-bottom-style: double; border-bottom-width: 2.25pt; text-align: center"><font style="font-size: 10pt">$2.75</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RenovaCare, Inc., together with its wholly owned subsidiary, focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp., completed the acquisition of its flagship technologies (collectively, the &#147;<b>CellMist<sup>TM </sup>System</b>&#148;) along with associated United States patent applications and two foreign patent applications, the first of which was filed on August 23, 2007 (DE 10 2007 040 252.1) and the second of which was filed on April 27, 2011 (DE 10 2011 100 450.9), both of which have been granted. One of the US patent applications was granted on November 29, 2016 (Patent No. US 9,505,000) and the other patent application was granted on April 4, 2017 (Patent No. US 9,610,430).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The CellMist<sup>TM</sup> System is comprised of (a) a treatment methodology for cell isolation for the regeneration of human skin cells (the &#147;<b>CellMist<sup>TM</sup> Solution</b>&#148;) and (b) a solution sprayer device (the &#147;<b>SkinGun<sup>TM</sup></b>&#148;) for delivering the cells to the treatment area. The Company has filed additional patent applications related to the CellMist<sup>TM</sup> Solution and SkinGun<sup>TM</sup> technologies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's activities have consisted principally of performing research and development activities and raising capital. These activities are subject to significant risks and uncertainties, including possible failure of preclinical testing and failing to secure additional funding before achieving sustainable revenue and profit from operations. The Company's ability to fund the development of its cellular therapies will depend on the amount and timing of cash receipts from future financing activities. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company&#146;s ability to establish itself as a profitable business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2017, the Company has a retained deficit of $12,893,784 and cash and cash equivalents of $442,941. In July 2017, the Company received Private Placement funding of $1.1 million. Based upon its current and near term anticipated level of operations and expenditures, the Company believes that cash on hand should be sufficient to enable it to continue operations through January 2018. If adequate funds are not available on reasonable terms, or at all, it would result in a material adverse effect on the Company&#146;s business, operating results, financial condition and prospects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In view of these conditions, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon achieving a profitable level of operations and on the ability of the Company to obtain necessary financing to fund ongoing operations. These consolidated financial statements do not give effect to any adjustments which will be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2016, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) No. 2016-09, &#147;Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)&#148;, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02, &#147;Leases (Topic 842)&#148;, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC Topic 842, Leases. ASU 2016-02 requires lessees to recognize a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months on its balance sheet. ASU 2016-02 also expands the required quantitative and qualitative disclosures surrounding leases. ASU 2016-02 is effective for the Company beginning January 1, 2019. Early adoption is permitted. The Company has determined that the adoption of ASU 2016-02 will currently have no impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2015, the FASB issued ASU No. 2015-17, &#147;Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes&#148; (&#147;ASU 2015-17&#148;). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09, &#147;Revenue from Contracts with Customers (Topic 606)&#148;, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017, and early adoption is permitted. The Company has determined that the adoption of ASU 2014-09 will currently have no impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company&#146;s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company presents both basic and diluted earnings per share (&#147;EPS&#148;) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following is the computation of basic and diluted net loss per share for the three and six months ended June 30, 2017 and 2016:</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" id="hdcell" style="text-align: center"><font style="font-size: 10pt"><b>Three Months Ended</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>Six Months Ended</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt"><b>Basic and Diluted EPS Computation</b></font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Numerator: </font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td colspan="2" style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Loss available to common stockholders' </font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(1,270,376</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(527,354</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(1,842,200</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">(1,308,245</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">)</font></td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Denominator: </font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Weighted average number of common shares outstanding</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">74,653,184</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">69,955,847</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">73,174,724</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">69,561,676</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Basic and diluted EPS</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.02</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.01</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.03</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">(0.02</font></td> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">)</font></td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares listed below were not included in the computation of diluted losses</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">per share because to do so would have been antidilutive for the periods presented:</p></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Stock options</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">545,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">437,500</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">545,000</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">437,500</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Warrants</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">2,228,908</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">6,796,087</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">2,228,908</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">6,796,087</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Convertible debt</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">633,656</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">633,656</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 11.25pt; text-align: justify"><font style="font-size: 10pt">Total shares not included in the computation of diluted losses per share</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">3,407,564</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">7,233,587</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">3,407,564</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify">&#160;</td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">7,233,587</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about stock options outstanding and exercisable at June 30, 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="5" style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>Stock Options Outstanding</b></font></td> <td>&#160;</td> <td colspan="5" style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt"><b>Stock Options Exercisable</b></font></td></tr> <tr style="vertical-align: bottom"> <td rowspan="4" style="width: 9%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Range of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Prices</b></p></td> <td style="width: 2%">&#160;</td> <td rowspan="4" style="width: 18%; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>Number of Shares Subject to Outstanding Options</b></font></td> <td style="width: 2%">&#160;</td> <td rowspan="4" style="width: 13%; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Contractual Life (years)</b></font></td> <td style="width: 2%">&#160;</td> <td rowspan="4" style="width: 11%; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Exercise Price</b></font></td> <td style="width: 2%">&#160;</td> <td rowspan="4" style="width: 11%; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"><b>Number of Shares Subject To Options Exercise</b></font></td> <td style="width: 2%">&#160;</td> <td rowspan="4" style="width: 13%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average Remaining Contractual</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Life (Years)</b></p></td> <td style="width: 2%; font: 12pt Times New Roman, Times, Serif; text-align: center">&#160;</td> <td rowspan="4" style="width: 13%; border-bottom: black 1pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">0.80</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">10,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">7.13</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">0.80</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">10,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">7.13</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">0.80</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.05</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">55,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">6.76</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.05</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">35,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">6.76</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.05</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.25</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">7.96</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.25</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">7.96</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.25</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.34</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">8.01</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.34</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">8.01</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.34</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.65</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">10,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">8.34</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.65</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">10,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">8.34</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.65</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.70</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">8.30</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.70</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">8.30</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.70</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.91</font></td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center">&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">130,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">8.71</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.91</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">130,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">8.71</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">1.91</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">2.28</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">9.06</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">2.28</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">7,500</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">9.06</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">2.28</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">4.20</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">310,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt">9.87</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt">4.20</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: right"><font style="font-size: 10pt">160,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt">9.87</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center"><font style="font-size: 10pt">4.20</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">Total</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right"><font style="font-size: 10pt">545,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: center"><font style="font-size: 10pt">9.12</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: center"><font style="font-size: 10pt">$3.09</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: right"><font style="font-size: 10pt">375,000</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: center"><font style="font-size: 10pt">8.94</font></td> <td>&#160;</td> <td style="font: 12pt Times New Roman, Times, Serif; border-bottom-style: double; border-bottom-width: 2.25pt; text-align: center"><font style="font-size: 10pt">$2.75</font></td></tr> </table> 11475 -1388381 -1308245 -1006278 -527354 1388381 1308245 1006278 527354 1164416 1122613 861393 453544 -453819 -264098 457 199 -0.03 -0.02 -0.02 -0.01 73174724 69561676 74653184 69955847 -13861 -13861 340735 340735 359265 359265 -764714 -1121442 -50000 -74750 544 35322 32216 -4160 11475 9113 -8489 17687 620872 274287 617878 1169 158 789624 1000000 445000 344624 1000000 24910 -121442 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based compensation has been included in the Consolidated Statement of Operations as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" id="hdcell" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Three Months Ended June 30,</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Six Months Ended June 30,</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2017</b></font></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td> <td style="text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Research and development</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">64,790</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">64,790</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="vertical-align: bottom; width: 1%; text-align: justify">&#160;</td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">General and administrative</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">553,088</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1,171</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">556,082</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify">&#160;</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">274,287</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify"><font style="font-size: 10pt">Total</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">617,878</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1,171</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">620,872</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; text-align: justify">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: justify"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><font style="font-size: 10pt">274,287</font></td> <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr> </table> 1100000 501425 447425 2.75 64790 64790 556082 274287 553088 1171 620872 274287 617878 1171 19338572 75000 9375 4 8 6000 344624 1000000 1.0223 460250 1123010 460250 410000 375000 EX-101.SCH 5 rcar-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Assets - Intellectual Property link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Contract Payable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Common Stock and Warrants link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Common Stock and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Details ) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Assets – Intellectual Property (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Contract Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Common Stock and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Common Stock and Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stock Options (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stock Options (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Stock Options (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 rcar-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 rcar-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE